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Abstract 
The ability to interface with and program cellular function remains a challenging 
research frontier in biotechnology.  Although the emerging field of synthetic biology has 
recently generated a variety of gene-regulatory strategies based on synthetic RNA 
molecules, few strategies exist through which to control such regulatory effects in 
response to specific exogenous or endogenous molecular signals.  Here, we present the 
development of an engineered RNA-based device platform to detect and act on 
endogenous protein signals, linking these signals to the regulation of genes and thus 
cellular function. 
We describe efforts to develop an RNA-based device framework for regulating 
endogenous genes in human cells.  Previously developed RNA control devices have 
demonstrated programmable ligand-responsive genetic regulation in diverse cell types, 
and we attempted to adapt this class of cis-acting control elements to function in trans.  
We divided the device into two strands that reconstitute activity upon hybridization.  
Device function was optimized using an in vivo model system, and we found that device 
sequence is not as flexible as previously reported.  After verifying the in vitro activity of 
our optimized design, we attempted to establish gene regulation in a human cell line 
using additional elements to direct device stability, structure, and localization.  The 
significant limitations of our platform prevented endogenous gene regulation. 
We next describe the development of a protein-responsive RNA-based regulatory 
platform.  Employing various design strategies, we demonstrated functional devices that 
both up- and downregulate gene expression in response to a heterologous protein in a 
human cell line.  The activity of our platform exceeded that of a similar, small-molecule-
 vi 
responsive platform.  We demonstrated the ability of our devices to respond to both 
cytoplasmic- and nuclear-localized protein, providing insight into the mechanism of 
action and distinguishing our platform from previously described devices with more 
restrictive ligand localization requirements.  Finally, we demonstrated the versatility of 
our device platform by developing a regulatory device that responds to an endogenous 
signaling protein. 
The foundational tool we present here possesses unique advantages over 
previously described RNA-based gene-regulatory platforms.  This genetically encoded 
technology may find future applications in the development of more effective diagnostic 
tools and targeted molecular therapy strategies. 
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Chapter 1 
 
 
 
Introduction  
 I-2 
RNA is a versatile regulatory biomolecule 
Synthetic biology is a rapidly emerging field that promises to improve our ability 
to investigate and manipulate living organisms through the creation of novel biological 
tools and systems, with innovations supporting applications in health, energy, and 
biomanufacturing1–3.  While advances in DNA synthesis have enabled the construction of 
large genetic systems4, the capability to design and predictably regulate such systems lags 
behind.  Synthetic RNA-based gene-regulatory devices are uniquely poised to address 
this need. 
Once thought to be merely the intermediate between the genetic information 
stored in DNA and proteins that executed cellular function, RNA has been shown to 
perform a large diversity of functional activities, such as catalysis, metabolite binding, 
and gene regulation5–8.  In addition, functional RNA molecules have been described that 
can modulate their activity in response to cellular and environmental inputs.  For 
example, temperature-sensitive structural elements regulate gene expression in the heat 
and cold shock responses in bacteria9, and metabolite-binding elements control the 
expression of enzymes in biosynthetic pathways10–12.  To date most of these regulatory 
elements have been characterized in prokaryotes, but examples have been found in 
eukaryotes as well13.  The many examples of naturally-occurring, ligand-responsive 
RNA-based gene-regulatory elements, or RNA switches, serve as the raw materials and 
inspiration for novel synthetic RNA-based regulatory devices14. 
As with proteins, the ability of RNA to perform functional activities arises from 
its three-dimensional folded structure.  Unlike proteins, however, this structure is almost 
entirely determined by hydrogen-bonding, base-stacking, and electrostatic interactions 
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between the constituent monomers15.  The relative simplicity of RNA intramolecular 
interactions has enabled the design of software models that computationally predict the 
secondary structures and associated free energies of a given RNA sequence with a high 
degree of accuracy16–18.  Such software has greatly aided the design of engineered 
functional RNA molecules19,20.  Facile protein structure prediction is not yet feasible due 
to the complexity of protein folding, and therefore protein-based devices such as 
allosteric transcription factors are currently far more challenging to engineer than their 
RNA-based counterparts. 
 
 
Engineered RNA devices in eukaryotes enable dynamic modulation of 
gene expression in response to molecular and environmental signals 
Synthetic RNA switches achieve gene regulation through a variety of 
mechanisms, but they generally contain two core components.  The sensor component 
detects the input signal, such as a small molecule or protein, through a binding 
interaction, and the actuator component modulates gene expression through mechanisms 
such as transcription, post-transcriptional processing, translation, or messenger RNA 
(mRNA) stability.  Many RNA-based devices utilize architectures that also incorporate a 
transmitter component, which links the sensor and actuator components and transmits 
information between them by modulating the activity of the actuator based on the ligand 
bound state of the sensor.  The sensor component is typically an aptamer, an RNA 
sequence with high affinity and specificity for a small molecule or protein ligand.  Many 
such binding elements can be found in nature12,21, but new aptamers can be generated 
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with an in vitro selection method known as systematic evolution of ligands by 
exponential enrichment, or SELEX22,23.  This method can be used to generate aptamer 
sequences to theoretically any small molecule or protein ligand of interest. 
The earliest potential point of regulation of gene expression is transcription.  In 
one example, an RNA regulator of transcription that responded to the small molecule 
tetramethylrosamine (TMR) was demonstrated in Saccharomyces cerevisiae.  The TMR 
aptamer was linked to a transcriptional activator through a randomized transmitter 
component and functional devices were selected based on TMR responsiveness.  
Demonstrations of engineered ligand-responsive RNA-based regulators of transcription 
have not been reported to date in mammalian cells. 
RNA-based devices that modulate gene expression through post-transcriptional 
processing, such as splicing, have been demonstrated in yeast and human cells24,25.  
Proper assembly of the spliceosome requires recognition of specific exonic and intronic 
sequence elements, and researchers have shown that the accessibility of these elements 
can be regulated by ligand binding to aptamer sequences.  In one example, an aptamer for 
tetracycline was placed at the 5’ splice site in the precursor mRNA (pre-mRNA) of a 
fluorescent reporter gene in yeast20.  Binding of tetracycline altered the conformation of 
the region around the splice site, preventing splicing of the exons encoding the reporter 
gene and reducing expression by up to 32-fold.  In another example, protein-responsive 
RNA-based devices were used to control alternative splicing of different transgenes in 
human embryonic kidney 293 (HEK293) cells25.  Aptamers for three different proteins 
were placed in an intronic region such that protein binding to the aptamer sequences 
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prevented the exclusion of an exon containing a premature stop codon, thereby 
modulating the expression of the encoded transgene. 
RNA interference (RNAi) is another post-transcriptional processing mechanism 
that has been utilized in RNA-based devices for controlling target gene expression.  
RNAi is a powerful platform for gene regulation in higher eukaryotes that is based on 
complementarity between the RNA regulator and the target gene, where the regulators 
can be encoded in diverse forms including microRNAs (miRNAs), short hairpin RNAs 
(shRNAs), and small interfering RNAs (siRNAs)26.  These RNAi-based components 
must be processed by cellular protein machinery to silence gene expression, either 
through blocking translation initiation, interrupting polypeptide elongation, or degrading 
the transcript14.  Many RNA switches that modulate processing in response to ligand 
input have been demonstrated27,28.  In one example, a miRNA-based switch responsive to 
small molecules was demonstrated in HEK293 cells29.  Ligand binding to an aptamer 
integrated into the base of the miRNA stem prevented processing of the primary miRNA 
(pri-miRNA) by Drosha, thereby increasing target gene expression levels as a function of 
increasing ligand concentrations.  In another example, the aptamer for the archaeal 
ribosomal protein L7Ae was inserted in the loop region of an shRNA targeting an 
antiapoptotic gene27.  By simultaneously regulating a proapoptotic gene with a separate 
device, the authors were able to control apoptosis in HeLa cells. 
Regulation of translation initiation is a common mechanism employed by ligand-
responsive RNA switches.  Following the example of natural prokaryotic translation 
initiation riboswitches and their engineered counterparts10–12, the aptamer is placed in the 
5’ untranslated region (UTR) just upstream of the translation initiation codon, such that 
 I-6 
ligand binding prevents the ribosome from binding and assembling properly.  For 
switches responsive to small molecules30, ligand binding can stabilize structures that 
discourage ribosome assembly, while in other cases protein binding prevents ribosome 
association through steric hindrance31–33.  In one interesting study in HEK293T cells, 
protein binding to an aptamer in the 5’ UTR of a bicistronic mRNA selectively repressed 
translation of the upstream gene while not affecting internal ribosome entry sequence 
(IRES)-dependent translation of the downstream gene32. 
Finally, effective regulation of gene expression can be accomplished by 
controlling the stability of mRNA, usually by modulating the susceptibility of mRNA to 
cellular ribonucleases (RNases).  The ends of eukaryotic mRNAs are protected by the 5’ 
7-methyl-guanosine cap and the 3’ poly(A) tail, which themselves are bound by various 
proteins that circularize the transcript.  Directed cleavage in either of the UTRs or the 
coding region exposes the mRNA to rapid degradation by exoribonucleases.  In one 
engineered switch exploiting this phenomenon, an aptamer that binds the caffeine 
analogue theophylline was integrated into a hairpin recognized by the RNase Rnt1p, such 
that ligand binding prevented Rnt1p-mediated cleavage in yeast34.  Another type of 
device controlling mRNA stability is based on self-cleaving ribozymes, which will be 
described below. 
 
 
Ligand-responsive ribozyme switches 
Ribozymes are RNA enzymes that accelerate chemical reactions by adopting 
certain folded structures similar to peptide-based enzymes.  Natural ribozymes were first 
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discovered in Group I introns35, but have since been identified to be involved in many 
vital cellular processes from mRNA splicing36 to peptide synthesis37.  Many ribozymes 
catalyze the lysis of an RNA phosphodiester bond, either in its own strand (cis) or in a 
separate RNA molecule (trans), thereby cleaving it in two.  Hammerhead ribozymes, first 
discovered in plant viroids38 and shown to function in a variety of organisms39, rapidly 
catalyze self-cleavage through a phosphodiester isomerization mechanism (Figure 1.1).  
The cleavage site is located in the ribozyme’s catalytic core immediately downstream of 
the conserved NUX sequence, in which N is any nucleotide and X is either A, C, or U. 
 
 
Figure 1.1.  The phosphodiester isomerization mechanism of hammerhead ribozymes.  
Two nearby guanosines contribute to general base catalysis.  In this example, ‘X’ is 
cytidine.  Adapted from40. 
 
The Smolke laboratory has recently described a framework for constructing 
ribozyme-based gene-regulatory RNA devices19.  The framework provides a modular 
assembly strategy for building these RNA devices from a sensor component, made of an 
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RNA aptamer, an actuator component, made of a satellite RNA of tobacco ringspot virus 
(sTRSV) ribozyme41, and a transmitter component, made of a sequence that functionally 
couples the sensor and actuator components (Figure 1.2).  The transmitter component is 
rationally designed based on competitive hybridization events that enable the device to 
distribute between two primary conformations: one in which the input cannot bind to the 
sensor and the other in which the input can bind to the sensor.  Input binding shifts the 
distribution to favor the input-bound conformation as a function of increasing input 
concentration and is translated to a change in the activity of the actuator, where a 
‘ribozyme-active’ state results in self-cleavage of the device.  The RNA device is coupled 
to the 3’ UTR of the target gene, where ribozyme self-cleavage inactivates the transcript 
and thereby lowers gene expression independent of cell-specific machinery. 
 
 
Figure 1.2.  Assembly of a ribozyme switch from modular components.  The aptamer is 
shown in light brown, the stems are shown in black, the catalytic core is shown in 
magenta, and loops and bulges are shown in blue.  Adapted from42. 
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The precise design of the transmitter component determines whether the ribozyme 
switch will repress or enhance gene expression, unlike many of the switches described 
above, which are capable of regulating gene expression in only one direction.  RNA 
devices that function as either ON or OFF switches that convert a molecular input signal 
to increased or decreased gene expression output, respectively, have been demonstrated 
in yeast and mammalian cells19,42–46 (Figure 1.3).  After initial demonstration of ribozyme 
switches responsive to theophylline and tetracycline in yeast19, the framework was 
extended to provide a general approach for the engineering of multi-input, higher-order 
information processing devices, where two-input logic gates (AND, NOR, NAND, and 
OR gates), signal filters, band-pass filters, and programmed cooperativity operations 
were demonstrated42.  These ribozyme switches were also used to control T-cell 
proliferation in mice43, demonstrating phenotypic control in an animal model.  Other 
investigators have demonstrated switching activity of a theophylline-responsive ribozyme 
switch coupled to the 5’ UTR45,46, but this strategy can lead to nonspecific reduction of 
translation initiation due to the high degree of secondary structure upstream of the start 
codon. 
Ribozyme switches possess a significant advantage not shared by many other 
gene regulation platforms in that their mechanism of action does not require any cell-
specific machinery.  Ribozyme switches are therefore functional across different 
organisms, including bacteria47, yeast19, and mammalian systems43.  This allows rapid 
screening of devices generated by both rational and directed evolution design strategies in 
simple organisms48, optimizing device activity before transitioning to more complex 
organisms44. 
 I-10 
 
Figure 1.3.  Ligand binding stabilizes the aptamer-formed conformation.  In an ON 
switch, ligand (red disk) binding stabilizes the catalytically inactive conformation, 
preventing ribozyme self-cleavage and allowing translation of the gene of interest.  In an 
OFF switch, the ligand stabilizes the catalytically active conformation, inducing cleavage 
and gene repression.  The cleavage site is indicated with an arrow.  Coloring is the same 
as in Figure 1.2. 
 
However, ribozyme switches are somewhat limited in their effectiveness and 
range of capabilities.  First, they are generally limited to the regulation of transgenes, 
with endogenous gene regulation achievable only through the utilization of targeted 
chromosomal integration strategies, which are cumbersome in mammalian systems49,50.  
In contrast, switch platforms based on RNAi enable facile ligand-responsive regulation of 
endogenous genes27,28.  Second, to date only small-molecule-responsive ribozyme 
switches have been described, while other platforms have been shown to respond to 
protein ligands.  Third, ribozyme switches have not yet been able to achieve the high 
dynamic ranges and input sensitivities of other gene regulation systems.  Finally, the 
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mechanism of action, specifically the subcellular location where ribozyme cleavage 
occurs, has not been fully elucidated.  For other switch platforms, such as those based on 
modulation of transcription, splicing, or RNAi processing, choice of ligand is constrained 
by the known subcellular location of the mechanism of action.  It is desirable to elucidate 
similar details about ribozyme switches to determine which ligands the platform is 
capable of sensing. 
 
 
Applications 
Engineered RNA devices have been used for a variety of applications in 
eukaryotes.  In reconstituting useful biosynthetic pathways in new host organisms, it is 
important to regulate the expression levels of the enzymes to maximize their activity 
while efficiently exploiting cellular resources.  Ribozyme-based regulatory devices have 
been used as noninvasive sensors of enzymatic products. In one example in yeast, a 
ribozyme switch responsive to xanthine was used to control a fluorescent reporter gene19.  
When the yeast were fed xanthosine, the enzymatic conversion of xanthosine to xanthine 
was reported noninvasively by fluorescent output.  In an extension of this concept, a 
theophylline-responsive ribozyme switch controlling a fluorescent reporter gene was used 
in a high-throughput screen of a large enzyme library of a caffeine demethylase, 
identifying a variant with 33-fold improvement in catalytic activity over eight rounds of 
directed evolution51. 
Synthetic RNA switches have demonstrated applications for medical purposes in 
human cells.  In one notable example, an RNA switch controlling alternative splicing 
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modulated protein expression levels in response to nuclear factor κB (NF-κB) and β-
catenin, two signaling proteins with important roles in disease25.  The device was able to 
influence cell fate by controlling the levels of a gene conferring sensitivity to a drug that 
induces apoptosis.  In another example, ribozyme switches responsive to small molecule 
drugs were used to regulate the expression of the cytokines IL-2 and IL-15 in engineered 
T cells, thereby imparting drug-modulated control over T-cell proliferation and survival 
in vitro and in vivo43.  This latter system was demonstrated in a mouse model, 
highlighting the potential application of this technology to improving the safety and 
efficacy of adoptive immunotherapy strategies. 
The future holds many more potential applications in biosensors, biofuels and 
drug compounds from synthetic metabolic pathways, diagnostic tools, and next-
generation gene therapies.  Additionally, all new applications, as well as all of the 
demonstrations described above, provide insight into the underlying biological 
mechanisms on which they rely, increasing our understanding of natural systems and how 
to better manipulate those systems in the future. 
 
 
Scope of thesis 
This thesis describes the development of a synthetic RNA device platform for the 
regulation of gene expression in response to molecular signals.  As described in Chapter 
2, we began with the cis-acting ribozyme switch platform developed by Win and 
Smolke19, attempting to divide the structure into two RNA strands such that their 
annealing would reconstitute the functional device.  These trans-ribozyme-based devices 
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were designed to target synthetic sequences inserted into the 3’ UTR of the target gene 
and were expressed in human cells.  After optimizing the molecular design for maximal 
in vivo cleavage activity using a cis-ribozyme-based model system, the improved trans-
ribozyme was coupled with additional RNA elements intended to increase the likelihood 
of binding and cleavage of the target strand.  However, in vivo activity of trans-ribozymes 
was not established, likely due to the inability of the two RNA strands to properly 
hybridize inside the cell.  Chapter 3 describes the development of protein-responsive 
ribozyme switches.  We designed a variety of device architectures intended to respond to 
the bacteriophage MS2 coat protein through different switching mechanisms.  We 
developed a genetic system for quantitative characterization of the activity of these 
devices in human cells.  After demonstrating a range of regulatory capabilities among the 
various device designs, we investigated the impact of different MS2 subcellular 
localizations on device activity and found that the switch platform is able to respond to 
both cytoplasmic- and nuclear-localized ligand.  Finally, we designed ribozyme switches 
to respond to other protein ligands in order to demonstrate the versatility of our device 
platform.  Chapter 4 discusses future directions for this work and its contributions to the 
field.  
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Chapter 2 
 
 
 
Development of an RNA device framework that targets 
endogenous genes in human cells  
 II-2 
Abstract 
Ligand-responsive genetic control systems are important tools in synthetic 
biology.  Such tools are especially valuable when they include the capability to regulate 
endogenous genes.  Allosteric ribozyme switches have been designed based on 
hammerhead ribozymes and RNA aptamers, and have demonstrated programmable 
ligand-responsive genetic regulation in diverse cell types.  We attempted to adapt this 
class of cis-acting genetic control elements to function in trans.  Previous work has 
demonstrated the division of a cis-acting hammerhead ribozyme into an enzyme strand 
and a substrate strand that reconstitute catalytic activity upon annealing with one another.  
We developed a design strategy to divide the allosteric ribozyme switch into two strands, 
such that the sensor component is entirely contained within the enzyme strand.  We 
investigated the ability of our trans-ribozyme designs to regulate the expression of genes 
in trans in human cell lines.  Cleavage activity of the trans-ribozyme platform was 
optimized using cis-ribozymes as a model, and our results indicate that the ribozyme stem 
sequence is not as mutable as previously reported.  We verified the cleavage activity of 
our optimized trans-ribozyme design in vitro, and coupled that design to a variety of 
ancillary genetic elements to direct stability, structure, processing, and localization of the 
ribozyme transcript in vivo.  However, we were unable to demonstrate trans-ribozyme-
mediated gene silencing, likely due to deficiencies in trans-ribozyme transcript stability 
and localization.  
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Introduction 
The ability to regulate the expression of endogenous genes is a desired function 
for synthetic RNA-based control systems.  The capability to interact with and modulate 
endogenous genes enables the silencing of the negative effects of gene products from 
pathogenic RNA and aberrant messenger RNA (mRNA), forming the foundation for 
novel gene therapies and tissue engineering methodologies.  Such targeted gene silencing 
has been demonstrated in models of bacterial infection1, viral infection2–7, and cancer8–11.  
For example, ribozymes have been used to target multiple genes in the HIV genome, 
effectively inhibiting viral replication in both laboratory studies12,13 and clinical trials14–
16.  In another example, tumor growth and angiogenesis in a pancreatic cancer mouse 
model were inhibited by a short hairpin RNA (shRNA) targeting glycogen synthase 
kinase-3 β, an important serine/threonine protein kinase in tumorigenesis11. 
When regulating genes in mammalian cells using synthetic RNA devices, it is 
often desirable to control the activity of those devices in response to user-specified 
molecular inputs.  This is especially true in the case of cancer therapeutics, where an 
important strategy to increase the efficacy and safety of the therapy is to target the 
regulatory effect to diseased cells while leaving healthy cells unaffected.  Such ligand-
responsive RNA-based genetic control elements have been demonstrated in mammalian 
cells.  In one example, alternative splicing was modulated using switches responsive to 
cancer biomarkers, such that presence of the biomarker allowed expression of herpes 
simplex virus–thymidine kinase (HSV-TK), conferring sensitivity to the pro-drug 
ganciclovir17.  In another example, the balance between proapoptotic and antiapoptotic 
 II-4 
genes was controlled using shRNAs containing an aptamer for the archaeal ribosomal 
protein L7Ae, whose processing was inhibited by ligand binding18. 
There are several desirable features for an effective ligand-responsive gene-
regulatory device.  Many previously described platforms exhibit some of these key 
features, but very few exhibit all of them.  First, the device must be programmable to 
respond to different ligand inputs, turning gene expression either on or off in response to 
ligand binding.  Many of the reported ligand-responsive platforms are capable of 
modulating gene expression either up or down, but not both19–22.  Second, the basal level 
of activity and the switching range of the device must be readily tunable through small 
alterations to the design to easily adjust device function to application-specific levels.  
Third, the ligand sensor and gene-regulatory actuator components must be modular in 
assembly, such that the ligand-binding domain can be easily replaced with a sensor for a 
different input, and the actuator can be retargeted to regulate a different gene, without 
necessitating a full and lengthy redesign of the device.  Lastly, a device platform that is 
portable between organisms, such as microbes and higher eukaryotes, can allow for rapid 
prototyping and optimization of the device in simple organisms and later implementation 
in more complex organisms.  This property is limited to devices that incorporate actuators 
that do not depend on cell-specific machinery. 
RNA control elements derived from the hammerhead ribozyme of the satellite 
RNA of tobacco ringspot virus (sTRSV)23 have been demonstrated to exhibit these 
desired capabilities and thus provide a powerful ligand-responsive platform for 
mammalian gene regulation.  The allosteric ribozyme switch framework developed by 
Win and Smolke24 demonstrates programmable ligand-responsive genetic regulation 
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through a synthetic RNA device.  These devices transmit ligand sensing by an aptamer 
component into cleavage of the target gene’s mRNA by a ribozyme actuator component, 
which leads to degradation of the transcript and silencing of gene expression24.  The 
ribozyme switches can be programmed to respond to different ligand inputs through the 
incorporation of different aptamer sequences24.  The activity of ribozyme switches is 
readily tuned by altering individual nucleotides, which changes the three-dimensional 
folded state of the device, thus altering the basal level of catalytic activity and the energy 
difference between the active and inactive conformations.  This, in turn, determines the 
difference in gene expression between the ON and OFF states24,25.  The modular 
components of the ribozyme switch platform can be easily replaced without affecting 
device activity, and the switch can be placed in the 3’ untranslated region (UTR) of any 
gene of interest to regulate its expression24.  Finally, because ribozyme cleavage does not 
rely on any cell-specific machinery, the platform is highly portable between organisms, 
supporting rapid prototyping systems that allow designs to be screened in a microbial 
host such as yeast and optimized designs subsequently ported to mammalian cells with 
little change in function26. 
The primary limitation of the ribozyme switch platform, as with many other 
previously demonstrated ligand-responsive regulation devices, is that it cannot be used to 
control endogenous genes24,27.  Instead it is limited to the regulation of transgenes, as the 
cis-acting genetic actuator must be encoded in the region immediately neighboring the 
target gene.  However, previous work has demonstrated that the hammerhead ribozyme 
can function as two separate molecules, an enzyme strand and a substrate strand, that 
reconstitute catalytic activity upon annealing with one another28,29.  These trans-acting 
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ribozymes can be tailored to a specific target sequence through the identity of targeting 
arms that base-pair to regions in the target gene, and can thus be used to target 
endogenous genes.  In an early demonstration, a trans-ribozyme was programmed to 
target the gag gene of HIV-1, lowering levels of that transcript in human cells2. 
Since this initial demonstration of endogenous gene regulation, investigators have 
examined factors that determine the functional activity of trans-ribozymes in vivo.  Trans-
ribozymes were found to function far more effectively in the cytoplasm than the nucleus, 
and localization strategies have been employed to target trans-ribozyme transcripts to the 
cytoplasm30,31.  Taira and colleagues coupled trans-ribozymes to transfer RNA (tRNA) to 
take advantage of its cytoplasmic localization and stability29,31, and used a random library 
to screen the region linking the trans-ribozyme and tRNA for increased stability32.  
Another important factor is the secondary structure of both the trans-ribozyme and target 
transcripts, which can interfere with binding.  In one notable study, a trans-ribozyme was 
linked to an RNA helicase protein, which removed secondary structure from the target 
mRNA to allow proper binding and cleavage33.  However, there is disagreement in the 
field on the effectiveness of trans-ribozymes as gene-regulatory elements, as the studies 
on trans-ribozymes have rarely included a non-cleaving control trans-ribozyme to clearly 
demonstrate that observed levels of gene expression knockdown are due to mRNA 
cleavage from the ribozyme, rather than antisense effects as a result of binding of the 
trans-ribozyme to the transcript.  Indeed, one study investigating trans-ribozymes found 
that these gene-regulatory elements were no more effective at silencing their target gene 
than equivalent non-catalytic antisense sequences3. 
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We attempted to extend the cis-acting ribozyme switch platform developed by 
Win and Smolke24 to a trans-acting platform capable of regulating the expression of 
endogenous genes.  We divided the allosteric ribozyme switch into an enzyme strand and 
a substrate strand, such that the sensor component is entirely contained within the enzyme 
strand.  We sought to leverage all of the advantages of the existing cis-ribozyme switch 
platform while overcoming its limitation of being able to regulate only heterologous 
genes.  We designed three trans-ribozymes and placed their cognate target sequences in 
the 3’ UTR of a fluorescent reporter gene, which we integrated into the chromosome of a 
human cell line to model the targeting of an endogenous gene.  Based on our initial 
results indicating that the trans-ribozyme designs were unable to silence the target gene, 
we performed additional studies to optimize the cleavage activity and gene expression 
knockdown in a model cis-ribozyme architecture, which led to the development of an 
improved trans-ribozyme design.  We also varied the trans-ribozyme expression system, 
incorporating genetic elements intended to increase the ability of the trans-ribozyme to 
anneal to and cleave the target strand.  Our results indicate that the sequence flexibility of 
the trans-ribozyme is severely restricted, limiting the capability to design trans-ribozymes 
to target any gene of choice.  We were unable to demonstrate gene regulation in vivo 
from our trans-ribozyme designs, likely due to issues of trans-ribozyme transcript 
stability and localization. 
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Results 
Design of a trans-ribozyme-based regulatory element in human cells 
We first attempted to establish the capabilities of trans-acting RNA devices to 
regulate endogenous cellular transcripts in human cells.  The design of the trans-
ribozyme is based on a modification of a hammerhead ribozyme34 that was optimized to 
enhance cleavage activity in the presence of physiological Mg2+ concentrations and 
hybridization efficiency between the two strands.  As shown in Figure 2.1A, the sequence 
of the hammerhead ribozyme is divided in two at loop I, such that the cleavage site is 
located in the target transcript.  Stems I and III are formed through the hybridization of 
the ribozyme targeting arms to complementary regions of the target transcript, whereas 
stem II and loop II are entirely contained within the trans-acting ribozyme strand.  This 
places almost all of the nucleotides reported to be conserved in the enzyme strand, with 
only the conserved NUX cleavage site in the target strand35.  Such designs have shown 
higher cleavage activity in vitro than designs in which the ribozyme is divided at loop 
II34, and they are more directly adapted to the cis-ribozyme-based RNA device 
framework24, as any aptamer can then be integrated into loop II.  To maintain the tertiary 
interactions between nucleotides in loops I and II that have been shown to be necessary 
for catalytic activity at physiological Mg2+ concentrations36, stem I of the ribozyme 
strand contains a bulge that mimics loop I.  When the ribozyme strand and target 
transcript anneal the catalytic core is effectively reconstituted and the target strand is 
cleaved.  Integration of the target sequence in the flexible regulatory space of the 3’ UTR 
of a reporter gene enables knockdown of that gene through targeted cleavage and 
subsequent degradation of its mRNA (Figure 2.1B). 
 II-9 
 
Figure 2.1.  Structure and function of the trans-ribozyme.  (A) The hammerhead 
ribozyme in cis and trans forms.  The catalytic core is shown in magenta, loops and 
bulges are shown in blue, the ribozyme strand is shown in black, and the target strand is 
shown in purple.  The cleavage site is indicated with an arrow.  (B) The trans-ribozyme 
binds and cleaves the target sequence in the 3’ UTR of the gene of interest, destabilizing 
the transcript and reducing protein expression.  Partially adapted from Win and Smolke24. 
 
Preliminary studies previously performed in the Smolke laboratory focused on the 
optimization of trans-ribozyme activity under physiological conditions.  In vitro 
experiments on a trans-ribozyme derived from the sTRSV hammerhead ribozyme 
demonstrated that the length of the targeting arms significantly impacts hybridization 
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interactions, and therefore cleavage rate, at physiological Mg2+ concentrations.  
Specifically, cleavage activity was shown to be highest when the targeting arm 5’ of 
bulge I and the stem III targeting arm are 16 and 7 base pairs long, respectively.  
Preliminary experiments conducted in yeast showed limited trans-ribozyme activity (Kate 
Galloway, unpublished results), but we hypothesized that design modifications would 
allow higher activity to be achieved in human cells. 
The trans-ribozyme molecular design strategies address challenges in the cleavage 
activity and hybridization efficiency in adapting the unimolecular cis-acting system to the 
bimolecular trans-acting system.  However, in implementing a trans-ribozyme in a 
cellular system the next level of design must address the stability and localization of the 
trans-acting molecule, two critical factors in the efficacy of trans-acting RNA regulatory 
systems.  Preliminary experiments previously conducted in the Smolke laboratory have 
demonstrated that these two factors limit the regulatory activity of trans-ribozymes in 
yeast cells (Kate Galloway, unpublished results).  However, it is likely that differences in 
the time scales of RNA transcription, processing, trafficking, and degradation may allow 
trans-ribozymes to function more effectively in human cells than in yeast. 
Three trans-ribozymes were designed and tested in human cells (Figure 2.2).  Two 
of the trans-ribozymes are derived from previously studied34 hammerhead ribozymes: 
sTRSV and peach latent mosaic viroid (PLMVd).  The third trans-ribozyme is based on 
the core of PLMVd but has modified stems designed to target a sequence within the 
coding region of a yeast-enhanced green fluorescent protein (yEGFP).  The trans-
ribozymes are flanked immediately upstream and downstream by small hairpins, intended 
to insulate the trans-ribozyme sequence from the surrounding transcript and prevent 
 II-11 
intramolecular binding of the targeting arms, which must remain single-stranded in order 
to bind to the target sequence.  Each trans-ribozyme is coupled with a unique targeting 
sequence, such that hybridization of the targeting arms reconstitutes stems I and III, 
forming a catalytically active ribozyme.  The targeting sequences are placed within the 3’ 
UTR of EGFP such that cleavage can be detected by monitoring fluorescence levels.  
Additionally, the targeting sequences are placed in multiple copies within the 3’ UTR in 
order to examine the regulatory activity of the trans-ribozymes as a function of the 
number of target sites. 
 
 
Figure 2.2.  Structures of trans-ribozymes bound to target sequences.  Coloring is the 
same as in Figure 2.1. 
 
 
Characterization of initial trans-ribozyme designs in a human cell line 
The trans-ribozymes are expressed from either a cytomegalovirus (CMV) RNA 
polymerase II (Pol II) or a U6 RNA polymerase III (Pol III) promoter.  Pol II promoters 
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generally control the synthesis of mRNAs, which are capped on their 5’ ends with 7-
methylguanosine and polyadenylated on their 3’ ends.  The 5’ cap and poly(A) tail 
associate with one another through a complex of proteins, thereby forming a circular 
messenger ribonucleoprotein (mRNP) complex that exhibits greater resistance to 
decapping enzymes and thus increased stability.  In contrast, Pol III promoters generally 
control the synthesis of small non-coding RNAs, such as microRNAs (miRNAs) and 
small interfering RNAs (siRNAs), and do not have a 5’ cap or poly(A) tail.  The trans-
ribozyme gene is assembled on a plasmid containing the fluorescent reporter gene 
DsRed-Express, which enables gating for cells that have been transfected with the 
plasmid (Figure 2.3). 
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Figure 2.3.  Trans-ribozyme and target gene characterization system.  The trans-
ribozyme is inserted between two insulating hairpins in a multiple cloning site (red lines).  
The resulting plasmid is transfected into cells with EGFP and the target sequence stably 
integrated into the genome. 
 
EGFP and the target sequence(s) in its 3’ UTR are stably integrated into the 
genome of human embryonic kidney 293 (HEK293) cells using the Flp-In system to 
generate isogenic stable cell lines (Figure 2.3).  The gene is inserted into a plasmid 
backbone containing a Flp Recombination Target (FRT) site, thus allowing stable 
integration through genetic recombination in cell lines that have been engineered to 
contain a single copy of the FRT site in their genome.  Integrating the fluorescent reporter 
gene in this way enables effective modeling of the targeting of endogenous transcripts by 
exogenous trans-ribozymes. 
To quantify trans-ribozyme regulatory activity, stable cell lines expressing GFP 
with target sequence(s) were transiently transfected with a plasmid encoding a trans-
ribozyme (Figure 2.3).  GFP fluorescence was measured using flow cytometry, gating for 
transfected cells so that only cells harboring the plasmid encoding a trans-ribozyme were 
analyzed.  Decreased GFP fluorescence is expected to correlate with increased regulatory 
activity.  Analysis of the fluorescence of stable cell lines demonstrates that GFP 
constructs containing one copy of the target sequence are expressed at a higher level than 
GFP constructs containing multiple (2x or 4x) copies (Figure 2.4).  These results indicate 
that the presence of target sequences in the 3’ UTR may have some nonspecific effect on 
the expression of the target gene, potentially through transcript destabilization or 
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translational efficiency.  However, even with these nonspecific effects, the data clearly 
indicate that none of the trans-ribozyme designs are able to downregulate expression of 
the target gene in this assay (Figure 2.4). 
 
 
Figure 2.4.  Activity of trans-ribozymes.  GFP fluorescence levels are reported for stably 
integrated constructs encoding one or multiple copies of trans-ribozyme target sequences 
transfected with constructs encoding trans-ribozymes.  Mistargeting trans-ribozymes that 
do not bind to the target sequence are included for comparison.  Reported values are 
geometric mean ± s.d. from biological duplicates. 
 
There are two possible explanations for why the trans-ribozymes do not exhibit 
gene silencing activity.  One possibility is that the two strands may not properly anneal in 
vivo to form a catalytically active ribozyme.  A second possibility is that although the two 
strands properly anneal, the ribozyme as formed does not cleave at a sufficient rate to 
downregulate gene expression.  It has previously been demonstrated that ribozyme 
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
1800 
sTRSV 1x sTRSV 4x PLMVd 1x PLMVd 4x yEGFP 1x yEGFP 2x 
G
FP
 fl
uo
re
sc
en
ce
 (a
rb
itr
ar
y 
un
its
) 
mistargeting ribozyme 
U6 ribozyme 
CMV ribozyme 
 II-15 
cleavage rate is correlated with in vivo gene knockdown37, and specifically that if the 
cleavage rate is too low then gene regulation will not be observed. 
 
Cis-ribozymes as a model for optimizing in vivo cleavage activity 
To investigate whether the cleavage rate of the formed trans-ribozyme would be 
sufficient to observe knockdown in vivo, we designed Type I cis-ribozymes based on the 
sTRSV trans-ribozyme.  Such designs remove the variable of whether the two strands can 
properly anneal in the cell and allow investigation of gene knockdown through ribozyme 
cleavage.  K was formed by adding a GUUG tetraloop to the end of Stem III of the 
sTRSV trans-ribozyme (Figure 2.5), covalently joining the two strands into one.  W is 
based on K but more closely resembles wild-type sTRSV, and Y even more so; W has the 
stem III sequence of sTRSV and Y is identical to W but with the loop I sequence reverted 
to that of wild-type sTRSV.  CU is identical to Y except that the distal portion of stem I is 
integrated into a different position in bulge I.  CU LsIII is identical to CU but with stem 
III extended by four base pairs, and CU LsIII inversion is identical to CU LsIII but with a 
stem III A-U pair changed to U-A.  CK LsI, CK LsIII, and CK LsIV are all identical to 
CU LsIII but with the sequences of stem I, stem III, or both, respectively, from K.  U 
LsIII is identical to CU LsIII except that the distal portion of stem I is integrated into a 
different position in bulge I.  Finally, HHe-PLMVd is adapted from a previously 
described trans-ribozyme4, and 3-way AA and 3-way AAA are based on CU LsIII but 
include a three-way junction with an additional helix in stem I38. 
 
 II-16 
 
Figure 2.5.  Structures of cis-ribozymes used to model trans-ribozyme activity.  Stems 
are shown in black, the catalytic core is shown in magenta, and loops and bulges are 
shown in blue. 
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Characterization of Type I cis-ribozymes in a human cell line 
Each Type I cis-ribozyme was placed in the 3’ UTR of EGFP and gene regulation 
activity was measured in transient transfection assays by flow cytometry.  K exhibited 
very little activity, with GFP fluorescence 80% of the non-cleaving control (Figure 2.6), 
indicating that the sTRSV trans-ribozyme would likely not be able to silence its target in 
vivo.  The sequence of W is more closely related to wild-type sTRSV and Y even more 
so, and the activity of these designs reflects this.  The alteration of the stem I integration 
point in CU leads to greater activity, and the extension of stem III in CU LsIII leads to a 
level of activity approaching that of sTRSV, with 8% expression compared to non-
cleaving control.  Inversion of the A-U base pair had a small detrimental effect on 
activity, while the three CK designs exhibited better activity the more similar they were 
to CU LsIII.  Finally, U LsIII and HHe-PLMVd exhibited high levels of regulatory 
activity, while the 3-way designs showed little activity.  These results suggest that the 
sequences of the ribozyme stems are not as flexible as previously reported2,35,39–41. 
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Figure 2.6.  Activity of type I cis-ribozymes.  Type I cis-ribozymes model the activity of 
trans-ribozymes.  Relative GFP fluorescence levels are reported for transiently 
transfected constructs encoding ribozyme switch sequences.  Reported values are 
geometric mean ± s.d. from biological duplicates or triplicates and normalized to the non-
cleaving sTRSVctrl. 
 
 
Development of an improved trans-ribozyme 
Based on its high level of gene-regulatory activity CU LsIII was chosen as the 
basis for a new trans-ribozyme design (Figure 2.7A).  In vitro cleavage assays were 
performed to confirm the binding activity of the CU LsIII trans-ribozyme.  For these 
experiments, the trans-ribozyme and target strands were synthesized using in vitro 
transcription, purified, and denatured and renatured separately.  The RNA strands were 
then incubated together in a buffer representative of physiological conditions (500 µM 
MgCl2, 100mM NaCl, 50mM Tris-HCl (pH 7.5) at 37°C).  Under these assay conditions, 
CU LsIII exhibited a cleavage rate of ~0.3 min−1 (Figure 2.7B), which is comparable to 
the cleavage rates of other ribozyme switches successfully used to regulate gene 
expression in yeast and mammalian cells25,26.  The results suggest that the CU LsIII trans-
ribozyme is capable of binding and cleaving its target and should be capable of doing so 
in vivo at a rate sufficient for controlling gene expression levels. 
 
 II-19 
 
Figure 2.7.  The improved trans-ribozyme.  (A) Structure of the optimized CU LsIII 
trans-ribozyme.  (B) In vitro cleavage activity of the CU LsIII trans-ribozyme.  Cleavage 
of the internally radiolabeled target strand is monitored over time with PAGE, allowing 
calculation of the cleavage rate. 
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Incorporation of ancillary elements in the trans-ribozyme transcript to direct 
stability, structure, processing, and localization 
There are a number of reasons why the trans-ribozymes described above may not 
be able to effectively cleave their target transcripts in human cells.  The main obstacles 
are likely the stability of the trans-ribozyme strand in the cellular environment and the 
ability of this strand to bind to its target strand in the time scale of its lifetime.  These 
issues are related, in that the less time required for the trans-ribozyme strand to bind to its 
target the less time it needs to exist in the cell, and the higher the stability of the trans-
ribozyme strand the more time it will have to bind to its target.  To address these issues, 
we developed a variety of expression constructs incorporating ancillary genetic elements 
into the sequence context of the CU LsIII trans-ribozyme. 
When expressed from the CMV Pol II promoter, the trans-ribozyme is part of a 
longer transcript.  Since the trans-ribozyme may interact with other parts of the transcript 
in a way that disrupts binding and cleaving of the target strand, we designed a construct 
containing cis-ribozymes immediately upstream and downstream of the trans-ribozyme 
and its insulating hairpins (Figure 2.8A).  This construct was intended to function by 
cleaving the trans-ribozyme out of the transcript, potentially making the trans-ribozyme 
more accessible for binding to the target strand.  However, the trans-ribozyme strand may 
be highly unstable once excised from the rest of the mRNP, so we also designed a 
construct containing large hairpins internal to the cis-ribozymes (Figure 2.8B).  
Following cis-ribozyme cleavage these large hairpins are expected to stabilize the 5’ and 
3’ ends of the excised transcript, protecting the trans-ribozyme strand from RNA 
exonuclease activity.  These large hairpins were also tested in constructs without cis-
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ribozymes, in both the CMV Pol II and U6 Pol III promoter expression systems (Figure 
2.8C). 
 
 
Figure 2.8.  Trans-ribozyme ancillary elements.  (A) Cis-ribozymes cleave the trans-
ribozyme (with its insulating hairpins) out of the larger transcript.  (B) Large hairpins 
stabilize the ends of the trans-ribozyme strand after excision.  (C) Large hairpins stabilize 
Pol II and Pol III trans-ribozyme transcripts.  (D) tRNAVal stabilizes the trans-ribozyme 
transcript and localizes it to the cytoplasm. 
 
Alternatively, we inserted tRNAVal immediately upstream of the trans-ribozyme 
(Figure 2.8D), adapting work from Koseki and colleagues29.  They demonstrated that 
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their chimeric tRNA trans-ribozymes were highly stable in human cells and localized to 
the cytoplasm, and were able to cleave HIV-1 RNA in vivo31.  We attempted to reproduce 
their work in our experimental system, using their HIV-targeting Rz2, as well as 
replacing the HIV trans-ribozyme with CU LsIII. 
We assayed the ancillary elements with flow cytometry using transient 
transfections of stable lines as described above (Figure 2.3).  None of the ancillary 
elements conferred activity on the CU LsIII trans-ribozyme (Figure 2.9).  Additionally, 
we were unable to reproduce the activity of the HIV tRNA trans-ribozyme reported by 
Koseki and colleagues.  We hypothesized that the stability of the GFP reporter used in 
our studies might be too high, such that significant protein levels remain even when the 
associated mRNA is cleaved by trans-ribozymes, masking the knockdown effect.  To 
address this possibility, we replaced GFP with destabilized enhanced GFP (d2EGFP)42, 
which has a much shorter half-life than its parent.  However, this modification to the 
experimental system did not result in detectable trans-ribozyme activity. 
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Figure 2.9.  Activity of trans-ribozymes with ancillary elements.  GFP fluorescence 
levels are reported for stably integrated constructs encoding trans-ribozyme target 
sequences transfected with constructs encoding trans-ribozymes with ancillary elements.  
Reported values are geometric mean ± s.d. from biological duplicates and normalized to 
non-cleaving control trans-ribozymes. 
 
 
 
Discussion 
We attempted to develop a trans-acting version of the cis-acting ribozyme switch 
platform previously developed in the Smolke laboratory24.  Our trans-ribozyme 
architecture benefits from the previous engineering efforts directed to the cis-acting 
platform, in particular the design principles for aptamer integration with the ribozyme to 
build functional ligand-responsive gene-regulatory devices.  The trans-ribozyme switch 
platform should have the added advantage of being able to regulate endogenous gene 
targets in trans in response to specified molecular inputs.  However, there are additional 
requirements for such a trans-acting RNA device to function properly.  Specifically, the 
functional RNA must be expressed in the cell at an appropriate concentration and 
localized appropriately, the binding site on the mRNA target must be accessible, and 
once annealed the duplex must fold into a catalytically active conformation. 
Since we did not observe gene-regulatory activity from our initial trans-acting 
ribozyme designs (Figure 2.4), we first examined the ability of our designs to exhibit 
cleavage activity when annealed to the target sequence.  Specifically, we constructed and 
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characterized cis-ribozyme versions of our trans-ribozyme designs, which were more 
likely to fold into the desired conformation based on the unimolecular context.  Indeed, 
the cis version of the sTRSV trans-ribozyme exhibited minimal regulatory activity 
(Figure 2.6).  We investigated the effects of stem length, stem and loop sequence, and 
loop I integration position on in vivo activity.  We found that deviation from the sTRSV 
sequence in the ribozyme stems was detrimental to ribozyme function (Figure 2.6).  This 
was surprising given that the stem sequence has generally been considered to be mutable 
due to its sequence diversity among natural hammerhead ribozymes, unlike the highly 
conserved catalytic core35,39–41.  These investigations led to the design of a new trans-
ribozyme with a high degree of sequence similarity to sTRSV, which we used for all 
subsequent device optimization. 
Following development of the optimized trans-ribozyme design, we further 
explored modifications to the design of the expression system that would support a high 
level of expression of the trans-ribozyme transcript.  In particular, the transcription rate of 
the trans-ribozyme expression system was set to a high level by testing two strong 
promoters that act through different mechanisms, the CMV (Pol II) and U6 (Pol III) 
promoters.  We further introduced design elements to reduce the degradation rate of the 
trans-ribozyme transcript by incorporating large hairpins on the 5’ and 3’ ends of the Pol 
III transcript and the unprotected portion of the Pol II transcript following excision from 
the mRNP mediated by cis-ribozymes.  We also used a chimeric tRNA trans-ribozyme 
expression platform, which had previously been demonstrated to support gene regulation 
from a trans-ribozyme and shown to have a long half-life in vivo29. 
 II-25 
In addition to being present in cells at a sufficiently high concentration, a 
functional trans-ribozyme must also be localized to the same subcellular location as its 
target to be able to bind and cleave.  Co-localization of the trans-ribozyme and target 
strands has been shown to be important for activity3, and we hypothesized that the 
chimeric tRNA trans-ribozymes would be transported to the cytoplasm, increasing their 
local concentration in the vicinity of their target mRNA and thereby improving 
hybridization efficiency.  We incorporated hairpins immediately upstream and 
downstream of the trans-ribozyme to insulate it from the surrounding transcript, 
attempting to minimize misfolding that would occlude the targeting arms.  We 
demonstrated with in vitro cleavage assays that the trans-ribozyme is capable of 
annealing with and cleaving its target sequence under physiological conditions (Figure 
2.7). 
Despite optimization of cleavage activity in model cis-ribozymes and 
incorporation of design elements to increase trans-ribozyme stability in vivo, we were 
unable to demonstrate trans-ribozyme-mediated gene-regulatory activity (Figure 2.9).  
We demonstrated with model cis-ribozymes that cleavage activity was sufficiently high 
to produce a large amount of gene knockdown, and we showed that the in vitro cleavage 
activity of our improved trans-ribozyme was comparable to that of previously 
characterized in vivo functional cis-ribozymes in yeast a mammalian systems.  Taken 
together these results suggest that our trans-ribozyme did not function in vivo due to 
issues with transcript levels and co-localization with the target strand.  Our efforts to 
improve trans-ribozyme stability and localization did not resolve these issues. 
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One possible area for further investigation is target site accessibility, which we 
did not address with any of our designs.  It has been shown that in a typical mRNA many 
target sites will be inaccessible due to secondary and tertiary structure33,35.  Optimization 
of target site location within the target mRNA strand could lead to functional trans-
ribozymes.  However, successful regulation of an endogenous gene could require 
extensive screening of many trans-ribozymes targeting different target sites.  Another 
possible strategy is employing RNA localization elements to target trans-ribozyme 
transcripts to the specific subcellular location of the mRNA target43,44, increasing the 
local effective concentration and increasing the likelihood of hybridization between the 
two strands. 
The finding that the sequence of the ribozyme stems is less flexible than expected 
coupled with the issue of target site accessibility severely limits the capability of trans-
ribozymes to target endogenous genes.  Furthermore, the independence of trans-
ribozymes from cell-specific machinery makes them vulnerable to degradation, while 
other methods for regulating endogenous genes, such as miRNA45 and clustered regularly 
interspaced palindromic repeats interference (CRISPRi)46, benefit from protein 
complexes that protect the RNA and facilitate interaction with the target strand.  Taken 
together, the limitations of the trans-ribozyme platform present a significant challenge to 
the regulation of endogenous genes, while other RNA-based platforms are more effective 
and promising.  Ligand-responsive miRNAs have previously been demonstrated45, and 
although allosteric regulation has not yet been demonstrated for CRISPRi, such capability 
may soon be realized.  These platforms may therefore be better poised to provide 
programmable ligand-responsive regulation of endogenous genes. 
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Methods 
Plasmid construction 
All plasmids were constructed using standard molecular biology techniques.  
Oligonucleotides were synthesized by Integrated DNA Technologies and the Stanford 
Protein and Nucleic Acid Facility.  Cloning enzymes, including restriction enzymes and 
T4 DNA ligase, were obtained from New England Biolabs.  Ligation products were 
electroporated into Escherichia coli DH10B (Life Technologies) using a GenePulser XP 
(Bio-Rad Laboratories) system using standard methods.  Clones were screened using 
colony polymerase chain reaction (PCR) and verified by sequencing (Laragen Inc. and 
Elim Biopharmaceuticals).  15% glycerol stocks were made from E. coli in logarithmic 
growth phase and stored at −80°C. 
A standardized cloning method was developed to facilitate insertion of trans-
ribozymes into various sequence contexts.  The DNA fragment insertFseI was inserted 
into pCS1036 (courtesy Yvonne Chen) (derived from pcDNA3.1(+) (Life Technologies)) 
between the restriction sites KpnI/XhoI to form pCS1576 (Figure 2.10), which contained 
a U6 and a CMV promoter for expressing trans-ribozymes and DsRed-Express as a 
transfection control.  Cassettes containing restriction sites, a terminator (U6 only), and 
small hairpins designed to prevent intramolecular binding of the trans-ribozyme targeting 
arms (U6 trans-ribozyme cassette and CMV trans-ribozyme cassette) were inserted 
downstream of the U6 (between BamHI/EcoRI) and CMV (between FseI/XhoI) 
promoters to form pCS1646 and pCS1662, respectively (Figure 2.10).  Ancillary cis-
ribozymes were inserted into pCS1662 between HindIII/KpnI and XbaI/ApaI to form 
pCS1955.  Ancillary large stabilizing hairpins were inserted into pCS1646 between 
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BamHI/BsrGI and AscI/ClaI and into pCS1662 between KpnI/FseI and XhoI/XbaI to 
form pCS1953 and pCS1954, respectively.  Both ancillary cis-ribozymes and large 
stabilizing hairpins were inserted into pCS1662 (using the same restriction sites used to 
form pCS1955 and pCS1954) to form pCS1956.  Trans-ribozymes were inserted into 
pCS1646, pCS1662, pCS1955, pCS1953, pCS1954, and pCS1956 between PacI/AgeI. 
 
 
eGFP 1585..2301
1572 KpnI (1)
1566 HindIII (1)
CMV 887..1474
375 EcoRV (1)
369 EcoRI (1)
346 BamHI (1)
2294 BsrGI (1)
2305 XhoI (1)
2311 XbaI (1)
2317 ApaI (1)
bGHpA 2348..2572
2601 MfeI (1)
2646 NruI (1)
CMV 2673..3229
DsRed-Express 3341..4031
bGHpA 4057..4281
SV40\PA 6133..6264
Neomycin 5165..5959
SV40 4760..5130
f1 4327..4755
Bla 8420..8322
pCS1036
8457 bp
12 BglII (1)
U6 17..347
5083 AvrII (1)
pUC 6646..7317
Ampicillin 8321..7461
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1933 NruI (1)
1888 MfeI (1)
bGHpA 1635..1859
1604 ApaI (1)
1598 XbaI (1)
1592 XhoI (1)
1581 FseI (1)
1572 KpnI (1)
1566 HindIII (1)
CMV 887..1474
375 EcoRV (1)
369 EcoRI (1)
346 BamHI (1)
U6 17..347
12 BglII (1)
CMV 1959..2516
DsRed-Express 2628..3318
bGHpA 3344..3568
f1 3614..4042
SV40\PA 5551..5420
Neomycin 4452..5246
4370 AvrII (1)
SV40 4047..4417
Ampicillin 7608..6748
Bla 7707..7609
pCS1576
7744 bp
pUC 5933..6604
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bGHpA 1727..1951
1696 ApaI (1)
1690 XbaI (1)
1684 XhoI (1)
1673 FseI (1)
1664 KpnI (1)
1658 HindIII (1)
CMV 979..1566
467 EcoRV (2)
461 EcoRI (1)
443 ClaI (1)
440 EcoRV (2)
432 AscI (1)
401 AgeI (1)
390 PacI (1)
355 BsrGI (1)
346 BamHI (1)
U6 17..347
12 BglII (1)
1980 MfeI (1)
2025 NruI (1)
CMV 2051..2608
DsRed-Express 2720..3410
bGHpA 3436..3660
Neomycin 4544..5338
4462 AvrII (1)
SV40 4139..4509
f1 3706..4134
pUC 6025..6696
Ampicillin 7700..6840
Bla 7799..7701
pCS1646
7836 bp
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bGHpA 1703..1927
1672 ApaI (1)
1666 XbaI (1)
1660 XhoI (1)
1629 AgeI (1)
1618 PacI (1)
1581 FseI (1)
1572 KpnI (1)
1566 HindIII (1)
CMV 887..1474
375 EcoRV (1)
369 EcoRI (1)
346 BamHI (1)
U6 17..347
12 BglII (1)
1956 MfeI (1)
2001 NruI (1)
CMV 2027..2584
DsRed-Express 2696..3386
bGHpA 3412..3636
f1 3682..4110
SV40\PA 5619..5488
Neomycin 4520..5314
4438 AvrII (1)
SV40 4115..4485
pUC 6001..6672
Bla 7775..7677
pCS1662
7812 bp
Ampicillin 7676..6816
DsRedEx 875..1553
869 BamHI (1)
CMV 223..812
161 MfeI (1)
12 BglII (1)
1558 AgeI (1)
1568 ClaI (1)
1578 XhoI (2)
1584 XbaI (3)
1590 ApaI (2)
1638 XhoI (2)
1644 XbaI (3)
1650 ApaI (2)
bGHpA 1681..1905
FRT 2189..2236
2216 XbaI (3)
2484 EcoRI (1)
HygroR 2244..3264
pUC 4582..3909
SV40 3396..3526
Bla 5686..5588
pCS2129
5723 bp
Ampicillin 5587..4727
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Figure 2.10.  Plasmid maps. 
 
The plasmid d2EGFP-Flp-In (courtesy Ryan Bloom) (derived from pcDNA5/FRT 
(Life Technologies)) was digested with NruI/EcoRV and blunt-end ligated to form 
pCS2129 (Figure 2.10), which contained DsRed-Express as a transfection control.  Trans-
ribozymes with tRNAVal 5’ and 3’ sequences were inserted into pCS2129 between 
BglII/MfeI. 
The DNA fragment insertAvrII was inserted into pCS1302 (courtesy Yvonne 
Chen) (derived from pcDNA5/FRT) between AvrII/ApaI to form pCS1592 (Figure 2.10), 
which contained a CMV promoter expressing EGFP.  Trans-ribozyme target sequences in 
one or multiple copies with spacers were digested out of pCS1306 and pCS1642 
(sTRSV), pCS1305 and pCS1495 (PLMVd), and pCS1492 and pCS1496 (yEGFP) 
EGFP 917..1654
917 KpnI (1)
911 HindIII (1)
CMV 232..819
206 NruI (1)
161 MfeI (1)
12 BglII (1)
1639 BsrGI (1)
1659 AvrII (1)
1668 XhoI (1)
1677 ApaI (1)
bGHpA 1708..1932
FRT 2216..2263
2243 XbaI (1)
2511 EcoRI (1)
HygroR 2271..3291
pUC 4609..3936
SV40 3423..3553
Ampicillin 5614..4754
Bla 5713..5615
pCS1592
5750 bp
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(courtesy Kate Galloway) and inserted into pCS1592 using AvrII/XhoI.  CU LsIII and 
HIV target sequences were inserted into pCS1592 between AvrII/XhoI to form pCS1966 
and pCS2603, respectively.  The coding region of d2EGFP was PCR amplified from the 
plasmid d2EGFP-Flp-In using the primers d2eGFP HindIII 62 F and d2eGFP AvrII 62 R 
and inserted into pCS1966 between HindIII/AvrII to form pCS2147.  The resulting 
plasmids were used to create isogenic stable cell lines through the Flp-In system (Life 
Technologies). 
Type I ribozymes with spacers were inserted into pCS1036, which contained a 
CMV promoter expressing EGFP and DsRed-Express as a transfection control, between 
XhoI/ApaI (Figure 2.10). 
 
Human cell culture 
Flp-In HEK293 cells (Life Technologies) were cultured in 10 mL (10 cm dish) or 
3 mL (6 cm dish) Dulbecco's Modified Eagle's medium (DMEM) (Life Technologies) 
supplemented with 10% fetal bovine serum (FBS) (Life Technologies) and 100 mg/L 
zeocin (Life Technologies) in a humidified incubator at 37°C and 5% CO2.  Cells were 
seeded at 2x104 cells/mL and passaged regularly using 0.25% trypsin-EDTA (Life 
Technologies), with media replaced every 48–72 hours.  Cells stably integrated with Flp-
In constructs were cultured similarly, except the cell culture media were supplemented 
with 100 mg/L hygromycin B (Life Technologies) and no zeocin. 
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Stable cell line generation 
Flp-In HEK293 cells were seeded at 1x105 cells/mL in 2 mL (6-well plate) 
DMEM with 10% FBS.  24 hours later the cells were cotransfected with a pcDNA5/FRT-
derived plasmid and pOG44 (Life Technologies) in a 1:9 ratio using FuGENE 6 or 
FuGENE HD (Promega) according to the manufacturer’s instructions.  Typically DNA 
and FuGENE were incubated together in Opti-MEM in a 1:3:50 (g:L:L) ratio for 
approximately 1 hour, with 2 mL samples receiving 2 µg of DNA.  24 hours after 
transfection the cells were resuspended using 0.25% trypsin-EDTA and DMEM with 
10% FBS, and ¼ of the cells were used to seed 2 mL (6-well plate) DMEM with 10% 
FBS.  24 hours later the media were replaced with DMEM with 10% FBS and 200 mg/L 
hygromycin B.  The media were replaced every 72–96 hours until macroscopic colonies 
were visible, usually after 10–14 days.  Colonies were pooled together with 0.25% 
trypsin-EDTA and passaged into DMEM with 10% FBS and 100 mg/L hygromycin B.  
10% dimethyl sulfoxide (DMSO) stocks were made from resuspended cells, cooled by 1 
degree/minute to −80°C, then stored at −320°C. 
 
Transient transfection 
Flp-In HEK293 cells were seeded at 1x105 or 3x105 cells/mL in 500 µL (24-well 
plate) DMEM with 10% FBS.  23–29 hours after seeding the cells were transfected with 
plasmid using FuGENE 6 or FuGENE HD according to the manufacturer’s instructions.  
Typically DNA and FuGENE were incubated together in Opti-MEM in a 1:3:50 (g:L:L) 
ratio for approximately 1 hour, with 500 µL samples receiving 500 ng of DNA. 
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Flow cytometry 
40–48 after transfection fluorescence data were obtained by flow cytometry using 
the Quanta Cell Lab Flow Cytometer equipped with a 488 nm laser (Beckman Coulter).  
Viability was gated by side scatter and electronic volume, and viable cells were further 
gated for DsRed expression, which served as a transfection control.  GFP and DsRed 
fluorescence was measured through 525/30 nm band-pass and 610 nm long-pass filters, 
respectively.  Data were analyzed using FlowJo (Tree Star Inc.).  Geometric mean values 
from biological replicates were reported with an error range of ±1 standard deviation.  
Geometric mean fluorescence values were normalized to those of a control with no 
ribozyme or an inactive ribozyme. 
 
In vitro cleavage assays 
The CU LsIII trans-ribozyme and its target strand were amplified by PCR from 
plasmids pCS1949 and pCS1966, respectively, using the primers CU HP T7 F and CU 
HP T7 R for the ribozyme strand and the primers Barcode T7 F and Barcode T7 R for the 
target strand.  The forward primers added the T7 promoter sequence.  Trans-ribozyme 
RNA was generated by in vitro transcription using 1 µg PCR product DNA as a template, 
with 40 mM Tris-HCl, pH 7.9, 16 mM MgCl2, 10 mM dithiothreitol (DTT), 2 mM 
spermidine, 3 mM rATP, rCTP, rGTP, and rUTP, 40 U RNaseOUT (Life Technologies), 
and 50 U T7 RNA polymerase (New England Biolabs) in 25 µL total volume and 
incubated at 37°C for approximately 2 hours.  The transcription product was treated with 
2 U of DNaseI (New England Biolabs) at 37°C for approximately 15 min and purified 
using the RNA Clean & Concentrator-25 kit (Zymo Research) according to the 
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manufacturer’s instructions.  Internally radiolabeled target strand RNA was generated by 
in vitro transcription using a similar method, except with rGTP reduced to 300 µM and 
supplemented with 5 µCi [α-32P]rGTP. 
Trans-ribozyme and radiolabeled target RNA were denatured separately by 
heating to 95°C in 50 mM Tris-HCl and 100 mM NaCl, then cooled by 1.2°C/minute to 
37°C.  Trans-ribozyme (1 µM final concentration) was added to target (100 nM final 
concentration) and the reaction was initiated by adding MgCl2 (500 µM final 
concentration) and incubating at 37°C.  Aliquots were removed and quenched with RNA 
stop/load buffer (95% formamide, 30 mM EDTA, 0.25% bromophenol blue, 0.25% 
xylene cyanol) on ice.  Reaction products were heated to 95°C for 5 min, snap cooled on 
ice for 5 min, and separated by 12% (w/v) denaturing polyacrylamide gel electrophoresis 
(PAGE) with 8.3M urea.  The 32P radioactivity of cleaved and uncleaved bands was 
quantified by phosphorimager analysis using a Molecular Imager FX (Bio-Rad 
Laboratories) and Quantity One software (Bio-Rad Laboratories). 
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Supplementary Tables 
Supplementary Table 2.1.  Primer and oligonucleotide sequences. 
Name DNA sequence 
insertFseI AAAGGCCGGCCAAA 
insertAvrII AAACTCGAGAAA 
sTRSV trans ATCCTCCAATCCTTTAGCTTTGACTCCTGATGAGTGGGTGACCACGAAACTGATGAC 
sTRSV target 
sequence GTCATCAGTCGAGTCATACTAAAGGATAGGAGGAAT 
PLMVd trans TCTTACTGAATTTACCTAACCCCACTGATGAGTCGCTGAAATGCGACGAAACTTTGCTT 
PLMVd target 
sequence AAGCAAAGTCTGGGGGGTAAATATCAAGTAAGA 
yEGFP trans AGCAGTAACAAATTCTTAAAACAACTGATGAGTCGCTGAAATGCGACGAAACCATGTG 
yEGFP target 
sequence CACATGGTCTTGTTAGAATTTGTTACTGCT 
CU LsIII trans ATCCTCCAATCCTTTATTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCTGAC 
CU LsIII ctrl 
trans 
ATCCTCCAATCCTTTATTTCCGGTGTACTGTGTCCGTGAGG
ACCGAACAGCTGAC 
CU LsIII target 
sequence GTCAGCTGTCACCGGATGTGCTAAAGGATAGGAGGA 
HIV trans ACACAACACTGATGAGGACCGAAAGGTCCGAAACGGGCAC 
HIV ctrl trans ACACAACACTAATGAGGACCGAAAGGTCCGAAACGGGCAC 
HIV target 
sequence GTGCCCGTCTGTTGTGT 
target sequence 
5' spacer TAAATCTAGGAAACAAA 
target sequence 
3' spacer ATAAACAAACTCGATCCGCGAAAAAACCGCGGA 
U6 trans-
ribozyme 
cassette 
GTCTGTACAGGTGTCTTCTTGAGCATGCTCAAGAGACATTA
ATTAAACAACCGGTACGTCCATTACAAAGTAATGGACGTG
GCGCGCCGATATCGATAAATTTTTTAAA 
CMV trans-
ribozyme 
cassette 
GGTGTCTTCTTGAGCATGCTCAAGAGACATTAATTAAACAA
CCGGTACGTCCATTACAAAGTAATGGACGT 
ancillary large 
hairpin U6 5' GTGTCACTTGCAGTATTAGCAAATAATACATGCAAGTGAC 
ancillary large 
hairpin U6 3' 
and CMV 
GTCACTTGCAGTATTAGCAAATAATACATGCAAGTGAC 
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ancillary cis-
ribozyme 5' 
AAACAAAATCCTTTATTTCCGGTCTGATGAGTCCGTGAGGA
CGAAACAGCTGACAAAAGTCAGCTGTCACCGGATGTGCTA
AAGGATAAAAAGA 
ancillary cis-
ribozyme 3' 
AAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTGAGGACGAAACAGCAAAAAGA 
tRNA 5' 
AGGACTAGTCTTTTAGGTCAAAAAGAAGAAGCTTTGTAAC
CGTTGGTTTCCGTAGTGTAGTGGTTATCACGTTCGCCTAAC
ACGCGAAAGGTCCCCGGTTCGAAACCGGGCACTACAA 
tRNA 3' GTCGGAAACGGTTTTTTTCTATCGCGTCGAC 
sTRSVctrl GCTGTCACCGGATGTGCTTTCCGGTACGTGAGGTCCGTGAGGACAGAACAGC 
sTRSV GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGC 
K ATCCTTTAGCTTTGACTCCTGATGAGTGGGTGACCACGAAACTGATGACGTTGGTCATCAGTCGAGTCATACTAAAGGAT 
W ATCCTTTAGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCAAAAGCTGTCACCGGATACTAAAGGAT 
Y ATCCTTTAGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCAAAAGCTGTCACCGGATGTTAAAGGAT 
CU ATCCTTTATTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCAAAAGCTGTCACCGGATGTGCTAAAGGAT 
CU LsIII ATCCTTTATTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCTGACAAAAGTCAGCTGTCACCGGATGTGCTAAAGGAT 
CU LsIII 
inversion 
ATCCTTTATTTCCGGTCTGATGAGTCCGTGAGGACGAAACT
GCTGACAAAAGTCAGCAGTCACCGGATGTGCTAAAGGAT 
CK LsI ATCCTTTATTTGACTCCTGATGAGTCCGTGAGGACGAAACAGCTGACAAAAGTCAGCTGTCGAGTCATGTGCTAAAGGAT 
CK LsIII ATCCTTTATTTCCGGTCTGATGAGTCCGTGAGGACGAAACTGATGACAAAAGTCATCAGTCACCGGATGTGCTAAAGGAT 
CK LsIV ATCCTTTATTTGACTCCTGATGAGTCCGTGAGGACGAAACTGATGACAAAAGTCATCAGTCGAGTCATGTGCTAAAGGAT 
U LsIII ATCGAATATGTGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCTGACAAAAGTCAGCTGTCACCGGATATTCGAT 
HHe-PLMVd 
GTGGTTCATAACACCTCTGATGAGTCGCTGAAATGCGACG
AAACCTCCTGAGCAAAAGCTCAGGAGGTCAGGTGTGAACC
AC 
3-way AA 
GGGATCAGTAAGGATGTGCTTTCCGGTCTGATGAGTCCGTG
AGGACGAAACAGCTGACAAAAGTCAGCTGTCACCACTGAT
CCC 
3-way AAA 
GGGATCAGTAAAGGATGTGCTTTCCGGTCTGATGAGTCCGT
GAGGACGAAACAGCTGACAAAAGTCAGCTGTCACCACTGA
TCCC 
A 5' spacer AAACAAACAAA 
A 3' spacer AAAAAGAAAAATAAAAATTTTTTGGAA 
B 5' spacer AATAAATAAAA 
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B 3' spacer CAAATAAACAAACACTC 
d2eGFP 
HindIII 62 F TAGAAGCTTATGGTGAGCAAGGGCGAGGAG 
d2eGFP AvrII 
62 R 
AAGCCTAGGTTTTGCTACACATTGATCCTAGCAGAAGCACA
GG 
CU HP T7 F TTCTAATACGACTCACTATAGGGTGTCTTCTTGAGCATGCTCAAGAGACATTAATTAAATCCTC 
CU HP T7 R ACGTCCATTACTTTGTAATGGACGTACCGGTG 
Barcode T7 F TTCTAATACGACTCACTATAGGACAAGTAACTCGAAAAACCTAGGTAAATCTAGGAAACAAAGT 
Barcode T7 R CTTTCTCGAGTCCGCGGTTTTTTCGC 
 
 
 
 
 
 
Supplementary Table 2.2.  Plasmid constructs. 
Plasmid Description 
pCS1592 pCS1302 with insertAvrII inserted between AvrII/ApaI 
pCS1631 pCS1592 with sTRSV target sequence with spacers inserted between AvrII/XhoI 
pCS1632 pCS1592 with sTRSV target sequence (4 copy) with spacers inserted between AvrII/XhoI 
pCS1629 pCS1592 with PLMVd target sequence with spacers inserted between AvrII/XhoI 
pCS1630 pCS1592 with PLMVd target sequence (4 copy) with spacers inserted between AvrII/XhoI 
pCS1633 pCS1592 with yEGFP target sequence with spacers inserted between AvrII/XhoI 
pCS1634 pCS1592 with yEGFP target sequence (4 copy) with spacers inserted between AvrII/XhoI 
pCS1966 pCS1592 with CU LsIII target sequence with spacers inserted between AvrII/XhoI 
pCS2063 pCS1592 with HIV target sequence with spacers inserted between AvrII/XhoI 
pCS1576 pCS1036 with insertFseI inserted between KpnI/XhoI 
pCS1646 pCS1576 with U6 trans-ribozyme cassette inserted between BamHI/EcoRI 
pCS1662 pCS1576 with CMV trans-ribozyme cassette inserted between FseI/XhoI 
pCS1655 pCS1646 with sTRSV trans inserted between PacI/AgeI 
pCS1653 pCS1646 with PLMVd trans inserted between PacI/AgeI 
pCS1657 pCS1646 with yEGFP trans inserted between PacI/AgeI 
pCS1685 pCS1662 with sTRSV trans inserted between PacI/AgeI 
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pCS1683 pCS1662 with PLMVd trans inserted between PacI/AgeI 
pCS1687 pCS1662 with yEGFP trans inserted between PacI/AgeI 
pCS1949 pCS1662 with CU LsIII trans inserted between PacI/AgeI 
pCS1955 pCS1662 with ancillary cis-ribozyme 5' inserted between HindIII/KpnI and ancillary cis-ribozyme 3' inserted between XbaI/ApaI 
pCS1956 
pCS1662 with ancillary cis-ribozyme 5' inserted between HindIII/KpnI, 
ancillary cis-ribozyme 3' inserted between XbaI/ApaI, and ancillary large 
hairpin U6 3' and CMV inserted between KpnI/FseI and XhoI/XbaI 
pCS1954 pCS1662 with ancillary large hairpin U6 3' and CMV inserted between KpnI/FseI and XhoI/XbaI 
pCS1953 pCS1646 with ancillary large hairpin U6 5' inserted between BamHI/BsrGI and ancillary large hairpin U6 3' and CMV inserted between AscI/ClaI 
pCS2012 pCS1955 with CU LsIII trans inserted between PacI/AgeI 
pCS2013 pCS1955 with CU LsIII ctrl trans inserted between PacI/AgeI 
pCS2014 pCS1956 with CU LsIII trans inserted between PacI/AgeI 
pCS2015 pCS1956 with CU LsIII ctrl trans inserted between PacI/AgeI 
pCS2010 pCS1954 with CU LsIII trans inserted between PacI/AgeI 
pCS2011 pCS1954 with CU LsIII ctrl trans inserted between PacI/AgeI 
pCS2008 pCS1953 with CU LsIII trans inserted between PacI/AgeI 
pCS2009 pCS1953 with CU LsIII ctrl trans inserted between PacI/AgeI 
pCS2129 pcDNA5/FRT with DsRed-Express inserted between BamHI/AgeI 
pCS2059 pCS2129 with tRNA 5' - CU LsIII trans - tRNA 3' inserted between BglII/MfeI 
pCS2060 pCS2129 with tRNA 5' - CU LsIII ctrl trans - tRNA 3' inserted between BglII/MfeI 
pCS2061 pCS2129 with tRNA 5' - HIV trans - tRNA 3' inserted between BglII/MfeI 
pCS2062 pCS2129 with tRNA 5' - HIV ctrl trans - tRNA 3' inserted between BglII/MfeI 
pCS1820 pCS1036 with sTRSVctrl with A spacers inserted between XhoI/ApaI 
pCS1819 pCS1036 with sTRSV with A spacers inserted between XhoI/ApaI 
pCS1816 pCS1036 with K with A spacers inserted between XhoI/ApaI 
pCS1817 pCS1036 with W with A spacers inserted between XhoI/ApaI 
pCS1818 pCS1036 with Y with A spacers inserted between XhoI/ApaI 
pCS2080 pCS1036 with CU with B spacers inserted between XhoI/ApaI 
pCS2081 pCS1036 with CU LsIII with B spacers inserted between XhoI/ApaI 
pCS2083 pCS1036 with CU LsIII inversion with B spacers inserted between XhoI/ApaI 
pCS1930 pCS1036 with CK LsI with A spacers inserted between XhoI/ApaI 
pCS1931 pCS1036 with CK LsIII with A spacers inserted between XhoI/ApaI 
pCS1932 pCS1036 with CK LsIV with A spacers inserted between XhoI/ApaI 
pCS2085 pCS1036 with U LsIII with B spacers inserted between XhoI/ApaI 
pCS2087 pCS1036 with HHe-PLMVd with B spacers inserted between XhoI/ApaI 
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pCS2088 pCS1036 with 3-way AA with B spacers inserted between XhoI/ApaI 
pCS2089 pCS1036 with 3-way AAA with B spacers inserted between XhoI/ApaI 
pCS2147 pCS1966 with d2EGFP inserted between HindIII/AvrII 
 
 
 
 
 
 
Supplementary Table 2.3.  Human cell lines with stably integrated constructs. 
Parental line Integrated plasmid construct 
Flp-In HEK293 pCS1631 
Flp-In HEK293 pCS1632 
Flp-In HEK293 pCS1629 
Flp-In HEK293 pCS1630 
Flp-In HEK293 pCS1633 
Flp-In HEK293 pCS1634 
Flp-In HEK293 pCS1966 
Flp-In HEK293 pCS2063 
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Chapter 3 
 
 
 
Development of an RNA device framework that responds to 
proteins in human cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Partially adapted from d’Espaux, L. D., Kennedy, A. B., Vowles, J. V., & Smolke, C. D. 
(2014). Development of protein-responsive ribozyme switches in eukaryotic cells. In 
preparation. 
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Abstract 
Synthetic molecular devices for programmable gene regulation in human cells are 
useful tools for studying biological systems and for developing novel diagnostic and 
therapeutic platforms.  Ribozyme switches are a class of gene-regulatory device that have 
been designed to exhibit programmable gene regulation activity in response to small 
molecule ligand inputs; however, response to protein ligands has not been demonstrated 
to date.  We developed ribozyme switches that respond to the bacteriophage MS2 coat 
protein and demonstrated ligand-responsive modulation of gene expression in a human 
cell line.  We investigated different strategies for device architecture and optimized the 
protein ligand to maximize sensitivity of the system, demonstrating up to 6.5-fold 
activation and up to 4.6-fold inhibition of gene expression from the ON and OFF switch 
platforms, respectively.  We also explored the mechanism of action and ligand 
localization requirements of the ribozyme switch by localizing the protein ligand to 
different cellular compartments.  We found that ligand localization to either the nucleus 
or the cytoplasm is sufficient for switching activity.  Finally, we extended the platform to 
the design of a ribozyme switch responsive to the endogenous signaling protein β-
catenin, demonstrating the ability of our platform to respond to an important disease 
marker.  
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Introduction 
Synthetic ligand-responsive genetic regulators are important tools for controlling 
diverse biological systems spanning from engineered microorganisms to human patients.  
Many small-molecule-responsive RNA-based switches have been demonstrated in 
eukaryotic systems, but fewer have responded to protein inputs1.  As changes in protein 
expression determine cellular phenotype, molecular devices that directly detect and 
respond to intracellular concentrations of proteins are important engineering tools.  Such 
genetically encoded devices have applications in the noninvasive detection and 
quantification of proteins in a complex cellular environment, as well as in targeting 
therapeutic activities to specific diseased cellular states. 
Several examples of mammalian gene control platforms have been described that 
utilize different architectures and gene-regulatory mechanisms.  One common strategy is 
the placement of an aptamer in the 5’ untranslated region (UTR) of the gene of interest, 
such that ligand binding causes translational repression by preventing proper ribosome 
assembly for initiating translation2–7.  In one example, binding of tryptophan RNA-
binding attenuation protein (TRAP) to its 5’ UTR binding site produced 180-fold 
translational repression2.  In another example, the archaeal ribosomal protein L7Ae was 
used to regulate two reporter genes simultaneously6.  However, this approach is limited to 
OFF switches unless it is coupled with an additional genetic inverter component8, and can 
respond only to cytoplasmic protein ligands.  Additionally, in mammalian cells 5’ UTR 
secondary structure can nonspecifically interfere with translation, further limiting this 
regulatory strategy. 
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The incorporation of other classes of gene-regulatory elements can further expand 
the capabilities of these protein-responsive switches.  For example, an L7Ae-responsive 
ON switch was created using a trans-acting regulator RNA that bound to the translation 
initiation site on the target messenger RNA (mRNA), thereby silencing gene expression4.  
Binding of L7Ae to its aptamer in the regulator RNA prevented binding to the mRNA, 
thereby derepressing expression of the target gene.  As another example, an L7Ae-
responsive ON switch based on an RNA interference (RNAi)-based silencing gene-
regulatory element was described that incorporated an aptamer in the loop region of the 
short hairpin RNA (shRNA), such that ligand binding in the cytoplasm masked the Dicer 
recognition site and prevented processing, inhibiting the gene silencing effect observed 
with proper Dicer processing in the absence of ligand9.  In a third example, ON and OFF 
switches modulating precursor mRNA (pre-mRNA) alternative splicing were used to 
control the inclusion of an exon containing a premature stop codon in response to 
endogenous protein disease markers in the nucleus10. 
Protein-responsive translational regulators have also been used to regulate genetic 
circuits in mammalian cells.  In one example, an L7Ae-responsive OFF switch was used 
to control L7Ae expression in a genetic feedback loop5.  In another example, that same 
switch was used in conjunction with an shRNA-based ON switch to precisely regulate the 
relative expression levels of a proapoptotic and an antiapoptotic gene, thereby controlling 
cell fate in HeLa cells9.  In addition, more complex genetic circuitry has been 
demonstrated by incorporating both protein-responsive translational regulators and small-
molecule-responsive transcriptional regulators to engineer genetic systems that perform 
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digital logic computations and fundamental arithmetic operations on prescribed 
molecular inputs3. 
One main advantage of post-transcriptional regulators such as those described 
above relative to transcriptional regulators is that they exhibit a faster change in gene 
expression in response to changes in the level of protein ligand.  When translation of the 
transcript is hindered or the transcript is degraded, synthesis of the encoded protein 
ceases, while the product of a transcriptionally silenced gene continues to be translated 
from existing mRNA.  However, generally the components in these regulatory devices 
are capable of either ON or OFF switching, but not both.  Rarely can the components be 
coupled without disrupting their individual functions, and the devices are generally not 
portable between microbes and higher eukaryotes.  A single gene-regulatory device 
platform capable of overcoming these limitations would present a more flexible and 
streamlined design process for devices tailored to different systems. 
Ligand-responsive ribozyme switches have been used to regulate gene expression 
in yeast11–13 and mammalian cells14–16.  Ribozyme switches are incorporated into the 
UTR of the target gene, where ligand-regulated cleavage of the transcript leads to 
silencing of gene expression11.  This platform possesses a number of important 
advantages that many of the protein-responsive devices demonstrated to date in 
mammalian cells lack.  First, ribozyme switches can be programmed to turn gene 
expression on or off in response to almost any ligand for which there exists an RNA 
aptamer.  Second, switch activity can be tuned through modifications to the sequence of 
the aptamer, ribozyme, and transmitter components.  Third, switch components can be 
modularly coupled without disrupting their activities.  Finally, ribozyme switches are 
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highly portably between different organisms because their mechanism of action is 
independent of cell-specific machinery11,17.  However, one current limitation of ribozyme 
switches is that the platform has only been demonstrated to respond to small molecule 
ligands.  It is also unknown where in the cell the ribozyme cleavage event occurs.  A 
protein-responsive ribozyme switch platform would leverage the important design 
advantages of the existing small-molecule-responsive platform while expanding its 
capability to process a new and important class of inputs. 
We describe the development of a protein-responsive ribozyme switch platform 
for regulating gene expression in mammalian cells.  We investigated a variety of device 
architectures, expanding beyond the design of the small-molecule responsive ribozyme 
switches, using an aptamer for the bacteriophage MS2 coat protein and controlling the 
expression of a fluorescent reporter gene.  We developed and optimized a genetic 
expression system for quantitative characterization of device activity in human cells.  The 
most highly active switch designs exhibited up to 6.5-fold activation and up to 4.6-fold 
inhibition of gene expression from the ON and OFF switch architectures, respectively.  
Experiments examining the impact of ligand localization on device activity indicated that 
the ribozyme switch platform is uniquely flexible in responding to ligands in either the 
nucleus or the cytoplasm.  Finally, we describe attempts to develop ribozyme switches 
responsive to other proteins and demonstrate a device responsive to the endogenous 
signaling protein β-catenin. 
 
 
 III-7 
Results 
Design of protein-responsive ribozyme switch platforms 
While previous work in the Smolke laboratory has demonstrated ligand-
responsive ribozyme switches, these studies have been limited to small molecule 
ligands11.  In developing protein-responsive ribozyme switch platforms we focused our 
initial designs on integration strategies for an aptamer to the bacteriophage MS2 coat 
protein (sensor) and the satellite RNA of tobacco ringspot virus (sTRSV) hammerhead 
ribozyme (actuator).  The MS2 protein and its natural stem-loop aptamer were selected as 
the initial ligand-aptamer pair for this study as they have been extensively used in cellular 
systems2,3,6,18–22 and as MS2 is a heterologous protein its levels can be readily controlled.  
Using this sensor and actuator we explored different design strategies for coupling these 
components in a way that would enable the binding of the protein ligand to affect the 
activity of the hammerhead ribozyme. 
The simplest design we explored was the direct-coupled architecture, in which the 
MS2 aptamer is directly coupled to either loop I or loop II of the hammerhead ribozyme 
(Figure 3.1, MS2-A), without any separate transmitter component linking the sensor and 
the actuator as incorporated in other small-molecule-responsive ribozyme switch 
platforms11.  We designed two different aptamer integration points in each of the loops, 
and we varied the loop I sequence.  The hypothesis underlying the direct-coupled 
architecture is that the relatively large size of the protein ligand MS2 would disrupt the 
ability of the ribozyme to fold into the catalytically-active three-dimensional structure, 
sterically interfering with the tertiary interactions between loops I and II that have been 
shown to be necessary for cleavage activity at physiological Mg2+ concentrations23.  The 
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direct-coupled architecture obviates the need to design the ribozyme switch to adopt 
distinct cleavage-active and cleavage-inactive conformations, and thus is a simpler design 
than strategies that incorporate directed secondary structure rearrangements.  However, it 
is possible that this design may be more dependent on the size of the protein ligand and 
the orientation by which the protein ligand binds to its aptamer. 
 
 
MS2-A 
MS2-D 
ON switch 
OFF switch 
MS2-C 
MS2-B 
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Figure 3.1.  MS2-responsive ribozyme switch designs.  MS2-A: The MS2 aptamer is 
coupled directly to the loop.  MS2-B: The MS2 aptamer is coupled through a transmitter 
affecting the secondary structure of stem II and the catalytic core.  MS2-C: The MS2 
aptamer is coupled through a transmitter affecting the secondary structure of the loop.  
MS2-D: The MS2 aptamer is placed directly upstream of the ribozyme and a transmitter 
affecting the formation of stem III.  The catalytic core is shown in magenta, loops and 
bulges are shown in blue, stems are shown in black, the transmitter is shown in green and 
red, the aptamer is shown in brown, and the MS2 ligand is shown in orange.  The 
cleavage site is indicated with an arrow.  See Supplementary Table 3.1 for sequences. 
 
We designed three additional ribozyme switch platforms that incorporated 
directed secondary structure rearrangements into distinct cleavage-active and cleavage 
inactive conformations.  The first set of ribozyme switches contains a transmitter 
designed to alter the secondary structure of one of the stems and the catalytic core (Figure 
3.1, MS2-B).  These ribozyme switches employ the same design strategy as previously 
developed small-molecule-responsive devices11, with sequence variations in loop I, the 
transmitter, and the aptamer.  The next set of designs contains a loop-transmitter that 
alters the secondary structure of the loop to which the aptamer is attached (Figure 3.1, 
MS2-C), which is expected to disrupt important tertiary interactions with the other loop.  
We designed an OFF switch, MS2-C1, in which the aptamer and loop-transmitter are 
integrated into loop I, and three ON switches with varied loop I sequences in which the 
aptamer and loop-transmitter are integrated into loop II.  In the final set of designs, the 
aptamer is not incorporated into the ribozyme, but is instead placed immediately 
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upstream in a sequential fashion (Figure 3.1, MS2-D).  Alternate hybridization between 
the aptamer stem and stem III of the ribozyme prevents the aptamer and ribozyme from 
folding simultaneously in ON switches, while OFF switches contain a competing hairpin 
that prevents the folding of the aptamer and ribozyme, unless ligand binding stabilizes the 
aptamer and prevents the competing hairpin from folding.  These six designs varied in the 
length and sequence identity of the transmitter component. 
 
Initial characterization of protein-responsive ribozyme switches in a human cell line 
The MS2-responsive ribozyme switch designs were tested for gene-regulatory and 
ligand-responsive activity in a human cell line.  The initial characterization construct was 
based on the ribozyme switch regulating a green fluorescent protein (GFP) reporter 
protein and measuring fluorescence under different MS2 levels through a flow cytometry 
assay.  Briefly, the ribozyme switches were located in the 3’ UTR of destabilized 
enhanced GFP (d2EGFP)24 expressed from a cytomegalovirus (CMV) promoter (Figure 
3.2).  A doxycycline-inducible expression cassette for MS2 was located on the same 
plasmid, in which an MS2-DsRed fusion protein was under the control of a CMV 
promoter with two tetracycline operator (TetO) sites located downstream of the promoter 
(CMV-TetO2).  The plasmid constructs were transiently transfected into a Flp-In T-REx 
human embryonic kidney 293 (HEK293) cell line, which stably expresses the tetracycline 
repressor (TetR).  Thus, in the absence of doxycycline transcription of the protein ligand 
is inhibited by TetR, and transcription is activated by the addition of doxycycline which 
inhibits TetR binding to the operator sites. 
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Figure 3.2.  Protein-responsive ribozyme switch characterization system.  A fluorescent 
reporter with ribozyme switch and a protein ligand are encoded on a plasmid.  A 
tetracycline-responsive CMV-TetO2 promoter controls expression of the protein ligand 
and the fluorescent reporter protein is expressed from a constitutive promoter.  The 
plasmid is transiently transfected into a Flp-In T-REx HEK293 cell line, which expresses 
the TetR repressor.  Addition of doxycycline derepresses the CMV-TetO2 promoter, 
turning on expression of the ligand, which regulates the activity of ON and OFF switches.  
The plasmid (with both fluorescent reporter and ligand genes) can used in transient 
transfection assays or stably integrated into the genome for stable expression assays. 
 
We tested four of the direct-coupled designs (MS2-A1, MS2-A2, MS2-A5, and 
MS2-A6) in the described in vivo characterization assay.  We selected designs that 
exhibited the highest in vitro cleavage rates in a surface plasmon resonance (SPR) assay 
(Andrew Kennedy, unpublished results).  We found that these ribozyme switch designs 
were able to downregulate GFP gene expression to varying degrees, but that cleavage 
activity was not attenuated by MS2 (Figure 3.3).  Subsequent in vitro switching assays 
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(Andrew Kennedy, unpublished results) confirmed that although these designs were 
capable of both cleavage and binding to MS2, ligand binding did not diminish cleavage 
activity.  These results suggest that although MS2 is approximately the same size as the 
ribozyme switch, binding alone is not sufficient to disrupt tertiary interactions between 
the loops and thus cleavage activity. 
 
 
Figure 3.3.  Activity of MS2-A designs.  Relative GFP fluorescence levels are reported 
for transiently transfected constructs encoding ribozyme switch sequences.  Reported 
values are geometric mean ± s.d. from biological duplicates and normalized to the 
absence of ribozyme. 
 
All other ribozyme switch platforms were tested using a slightly modified in vivo 
characterization construct. Specifically, the d2EGFP fluorescent reporter gene was 
replaced with blue fluorescent protein (BFP), the CMV promoter driving the expression 
of the reporter gene was replaced with the elongation factor 1 α (EF1α) promoter, and the 
MS2-DsRed fusion ligand was replaced with MS2 (Figure 3.2).  Flow cytometry assays 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
sTRSV MS2-A1 MS2-A2 MS2-A5 MS2-A6 
re
la
tiv
e 
G
FP
 fl
uo
re
sc
en
ce
 
MS2-A 
uninduced 
induced 
 III-13 
were performed on a Flp-In T-REx HEK293 cell line transiently transfected with the 
ribozyme switch constructs.  The transmitter designs (MS2-B) showed low to moderate 
amounts of gene knockdown activity, with three designs, MS2-B2, MS2-B3, and MS2-
B7, exhibiting 1.8-, 1.3-, and 1.5-fold, respectively, increases in gene expression in 
response to doxycycline-induced MS2 (Figure 3.4, MS2-B).  MS2-B2 showed the highest 
switching activity of all designs tested, although its high basal expression level may limit 
its usefulness in future applications. 
One of the loop-transmitter designs (MS2-C) showed low gene knockdown and 
no switching activity (MS2-C2), while the other three designs responded to MS2 (Figure 
3.4, MS2-C).  MS2-C3 exhibited a high level of gene knockdown activity, with gene 
expression almost as low as sTRSV, and the second highest switching activity (1.6-fold 
increase).  MS2-C1 was the only functional OFF switch tested, exhibiting 1.4-fold 
reduction in gene expression in response to MS2. 
The sequential designs (MS2-D) showed the highest levels of gene knockdown 
activity, with three designs, MS2-D3, MS2-D5, and MS2-D6, exhibiting gene expression 
as low as sTRSV (Figure 3.4, MS2-D).  MS2-D5 showed the highest switching activity 
(1.5-fold) of the sequential designs. 
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Figure 3.4.  Activity of MS2-B, MS2-C, and MS2-D designs.  Relative BFP fluorescence 
levels are reported for transiently transfected constructs encoding ribozyme switch 
sequences.  Reported values are geometric mean ± s.d. from biological duplicates and 
normalized to the non-cleaving sTRSVctrl. 
 
Non-cleaving control versions of three ribozyme switches (MS2-B2ctrl, MS2-
C1ctrl, and MS2-C3ctrl) were constructed and tested under identical assay conditions.  
The control designs did not exhibit gene knockdown activity or responsiveness to MS2 
(Figure 3.4).  These results indicate that gene knockdown is due to ribozyme cleavage 
rather than to an effect of device secondary structure alone, and that ligand 
responsiveness is due to modulation of cleavage rather than an effect of ligand binding 
alone.  Eight designs (MS2-B1, MS2-B2, MS2-B3, MS2-B7, MS2-C1, MS2-C3, MS2-
C4, and MS2-D5) were subjected to further testing. 
 
Development of an improved genetic system for quantitative characterization of 
ribozyme switch activity in vivo 
In order to more accurately measure the gene-regulatory activity of the protein-
responsive ribozyme switches in mammalian cells, we developed and optimized an 
improved in vivo characterization system.  As described above, the initial characterization 
system for the ribozyme switches (Figure 3.2) measured activities through transient 
transfection assays in order to quickly screen device designs for activity.  However, the 
ease of this screening method is accompanied by a high degree of variability.  For 
example, in a transient assay different cells in the transfected population receive different 
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amounts of plasmid, such that cells in the transfected population can exhibit a range of 
gene expression over three orders of magnitude, and a large portion of cells receives no 
plasmid at all (Figure 3.5).  To measure ribozyme switch activity, analysis must be 
performed on transfected cells only, which was accomplished by gating for cells that 
expressed a fluorescent protein as a transfection marker.  One method that we used to 
determine the transfected population was to cotransfect a plasmid encoding the 
expression of a second fluorescent protein with the plasmid encoding a ribozyme switch 
and its reporter gene.  Control experiments in our laboratory have shown that in such 
cotransfection experiments nearly all transfected cells contain both plasmids (Kathy Wei 
and Joy Xiang, unpublished results).  An alternative method we used to determine the 
transfected population was to gate transfected cells based on the expression of the 
reporter gene regulated by the ribozyme switches.  While cell populations exhibiting a 
high level of gene expression are fully distinct from populations of untransfected cells, 
this is not so for cells expressing devices with high gene silencing activity, with some 
transfected cells exhibiting similar fluorescence levels as untransfected cells (Figure 3.5).  
Such devices therefore exhibit an artificially high level of gene expression after gating by 
this method, as the transfected cells with the lowest gene expression levels have been 
removed from the analysis.  While this effect may result in elevated expression levels for 
these switches, it does not obscure our ability to observe the switching activity associated 
with these switches, even for devices with the lowest levels of gene expression (Figure 
3.4, MS2-D5 and MS2-D6). 
To avoid the variability and efficiency issues inherent in transient transfections, 
we examined the characterization of constructs that had been stably integrated into the 
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genome of the cell line as an alternative approach.  We used the Flp-In integration system 
with an HEK293 cell line containing a Flp Recombination Target (FRT) site in its 
genome.  This system allows an expression vector to be integrated into the genome via 
Flp recombinase-mediated recombination at the FRT site.  The resulting isogenic stable 
cell line presents a homogenous level of gene expression across all cells in the 
population, although this level is lower than that produced by the same construct when 
transiently transfected (Figure 3.5).  As cells with the desired integration are selected by 
culturing the transfected cells in selective media, the integration process requires 2–3 
weeks to generate isogenic stable cell lines.  To ensure maximum flexibility in ribozyme 
switch characterization, the characterization plasmids were constructed on a backbone 
that was compatible with both transient transfection and stable integration procedures 
(Figure 3.2). 
 
 
Figure 3.5.  Histograms of transiently transfected and stably integrated fluorescent 
constructs.  Transient transfection is not highly efficient and results in a large population 
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of untransfected cells (red).  Gating to remove those cells from analysis also removes a 
portion of a population of cells expressing a device with a high level of gene silencing 
(orange).  Stable integration of a construct yields a highly homogenous population 
(green) with lower mean fluorescence than cells transiently transfected with that 
construct (blue). 
 
As described above, our initial characterization construct utilized a GFP reporter 
expressed from a CMV promoter to measure the gene-regulatory activity of the ribozyme 
switches.  These constructs encoded a protein ligand expression cassette in which an 
MS2-DsRed fusion was expressed from a doxycycline-inducible CMV-TetO2 promoter.  
We observed that when these constructs were stably integrated into Flp-In T-REx 
HEK293 cells, the resulting stable cell lines produced no detectable fluorescent signal 
from the MS2-DsRed fusion in response to doxycycline.  In contrast, when using the 
same constructs in transient transfection assays, doxycycline did elicit a detectable 
fluorescent signal, albeit low, from the MS2-DsRed fusion.  Our control experiments 
indicated that the expression from the stably integrated constructs were generally lower 
than that from the same constructs in a transient transfection assay (Figure 3.5).  Thus, we 
concluded that under stable expression conditions the levels of the MS2-DsRed ligand 
were reduced below the detection threshold of the flow cytometry assay. 
To improve characterization of the protein responsiveness of the ribozyme 
switches in the stable expression assay, we modified the protocol to increase protein 
ligand levels by transiently transfecting a plasmid encoding the expression of MS2 or the 
MS2-DsRed fusion into the stable cell lines prior to analysis.  However, in the course of 
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optimizing the protocol for this assay, we noticed two unexpected effects that confounded 
analysis of the gene-regulatory activity and ligand-responsiveness of the ribozyme 
switches.  First, transient transfection of d2EGFP-expressing cell lines resulted in a 
population of cells with lower GFP fluorescence levels than untransfected cells, but not 
as low as parental cells expressing no fluorescent proteins (Figure 3.6A).  The appearance 
of this cell population was observed for transfection of plasmids encoding expression of 
fluorescent proteins, non-fluorescent proteins, and no proteins (i.e., a plasmid with no 
mammalian promoters).  Transfection of a plasmid encoding a different fluorescent 
reporter protein, BFP, under the control of a different promoter, EF1α, also led to this 
effect, ruling out promoter competition as a cause of the knockdown.  Importantly, this 
effect was not observed when an “empty” transient transfection was performed, 
containing transfection reagent but no plasmid. 
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Figure 3.6.  Effects of transient transfection of stable cell lines expressing a fluorescent 
reporter protein.  (A) Histograms of a d2EGFP stable cell line (blue), that stable line 
transfected with a plasmid encoding MS2-DsRed (orange), and the no color parental cell 
line (red).  (B) Two color scatter plots of a d2EGFP stable cell line, showing the small 
population of cells (arrow) transfected with a plasmid encoding MS2-DsRed that exhibit 
higher GFP fluorescence than the stable line itself.  (C) Histograms of a BFP stable cell 
line (blue), that stable line transfected with a plasmid encoding MS2-DsRed (orange), and 
the no color parental cell line (red).  (D) Two color scatter plots of a BFP stable cell line 
transfected with a plasmid encoding MS2-DsRed. 
 
The second confounding effect resulting from transient transfection of plasmids 
encoding MS2-DsRed into the cell lines stably expressing d2EGFP was an increase in 
GFP fluorescence in cells with the highest DsRed fluorescence to levels higher than the 
untransfected cell population (Figure 3.6B).  Such an effect can be expected from 
spillover between fluorescence channels due to overlap of the fluorescent protein 
emission spectra; however, compensation is generally performed to correct for such 
effects.  In this case, the effect remained after proper compensation, and even after over-
compensation, suggesting that it is not due to spillover between fluorescence channels.  
This effect is especially problematic as it is similar to the changes we would expect to 
observe in GFP fluorescence as a result of the gene-regulatory activity of an MS2-
responsive ribozyme switch, with ligand binding to the ribozyme switch preventing 
cleavage and thereby increasing gene expression.  However, the effect was also observed 
with plasmids encoding DsRed without the MS2 ligand, and in stable lines that did not 
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contain a ribozyme switch.  We therefore concluded that the increase in GFP 
fluorescence was not a result of ribozyme switch activity. 
To address both of these problems, we redesigned our characterization system 
such that the ribozyme switches were placed in the 3’ UTR of BFP, which was under the 
control of an EF1α promoter.  Stable cell lines expressing BFP did not exhibit 
nonspecific knockdown or fluorescence increases as a result of transient transfection of 
plasmids, including plasmids encoding the MS2-DsRed fusion (Figure 3.6C and D).  This 
redesigned and optimized characterization system was used for all subsequent ribozyme 
switch characterization assays, including investigations of the transmitter designs (MS2-
B), the loop-transmitter designs (MS2-C), and the sequential designs (MS2-D). 
 
MS2 variants result in optimization of switch sensitivity to ligand 
In our initial screening we observed a moderate amount of switching activity from 
a subset of our MS2-responsive ribozyme switch designs.  We next examined whether we 
could improve ligand sensitivity, and thus switching activity, of these designs by 
optimizing the ligand itself.  MS2 binds to its aptamer in the dimerized form25.  However, 
once bound the wild-type protein will multimerize to form a capsid26.  We hypothesized 
that multimerization of the ligand could negatively impact switching activity.  Thus, we 
examined two alternative versions of the MS2 ligand: (i) a mutant form of MS2 
(MS2mut) containing two amino acid substitutions (V75E and A81G) that is deficient in 
capsid formation but retains the RNA binding affinity of the wild-type protein27 and (ii) a 
fused dimer of the MS2 mutant (2MS2mut).  The dimer forms in a head-to-tail 
orientation, and the fused dimer joins the N- and C-termini together with the deletion of 3 
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amino acids at the junction.  A similar fused dimer without the V75E/A81G substitutions 
has been shown to retain the same RNA binding affinity as wild-type28. 
We assayed a subset of ribozyme switch designs for sensitivity to these MS2 
variants using the improved characterization system (Figure 3.2).  We tested the subset of 
designs that responded to MS2 in our initial screening experiments, as well as MS2-B1 
because it showed substantial switching activity in yeast assays (Leopold d’Espaux, 
unpublished results).  We performed the assay using transient expression, similar to our 
initial experiments with the MS2-B, MS2-C, and MS2-D designs, with MS2mut or 
2MS2mut replacing MS2 on the plasmid.  Our results indicate that although device basal 
levels remained mostly unaffected by the change in ligand (as expected), all switches 
tested were equally or more responsive to MS2mut than MS2 (Figure 3.7A).  In addition, 
most of the switch designs exhibited even greater sensitivity to the 2MS2mut ligand, 
including MS2-B1, which showed no response to MS2 or MS2mut under identical assay 
conditions.  These results indicate that preventing ligand multimerization is beneficial for 
switch sensitivity.  The increase in sensitivity to 2MS2mut is likely due to increased 
effective ligand concentration.  As the MS2 monomer must dimerize in order to bind to 
the aptamer25, expressing the protein as a fused dimer roughly doubles the effective 
concentration of the ligand. 
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Figure 3.7.  Activity of ribozyme switches with optimized ligands.  (A) Switch response 
to wild-type MS2, MS2 V75E/A81G (MS2mut), and the fused dimer of MS2mut 
(2MS2mut).  BFP fluorescence levels are reported for transiently transfected constructs 
encoding ribozyme switch sequences.  Reported values are geometric mean ± s.d. from 
biological duplicates.  (B) Switch response to 2MS2mut, including two new switch 
designs. Relative BFP fluorescence levels are reported for transiently transfected 
constructs encoding ribozyme switch sequences cotransfected with a transfection control 
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plasmid.  Reported values are geometric mean ± s.d. from biological duplicates and 
normalized to the non-cleaving sTRSVctrl. 
 
We used the results from this assay and our optimized ligand to further explore 
improvements to the ribozyme switch designs.  MS2-B2 differs from MS2-B1 in the 
sequence of loop I, and we hypothesized that this difference may be the cause of the 
increased gene knockdown and switching activities observed for MS2-B2.  We modified 
the designs of MS2-B3 and MS2-B7 by changing their loop I sequences to that of MS2-
B2, generating MS2-B10 and MS2-B11, respectively.  We assayed these new designs 
with our optimized ligand 2MS2mut (Figure 3.7B).  MS2-B11 exhibited the greatest 
response to ligand (4.1-fold), while the OFF switch MS2-C1 exhibited 3.8-fold 
switching. 
 
Protein ligand localization allows probing of ribozyme switch mechanism of action 
We next investigated how the subcellular localization of ligand affected ribozyme 
switch activity.  For ribozyme switches responsive to small molecules previously 
developed in the Smolke laboratory11 it is expected that the ligand will freely diffuse 
throughout the cell, available to bind to its aptamer over the entire lifetime of the mRNA, 
from transcription in the nucleus to translation in the cytoplasm.  Proteins, however, are 
commonly localized to specific subcellular locations.  Localization of the protein ligand 
enables the investigation of where in the cell the ribozyme cleaves, and consequently 
when it cleaves relative to mRNA nuclear export and translation.  In the case of an ON 
switch, where ligand binding is required to prevent ribozyme cleavage, the ribozyme 
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switch may be unresponsive if the ligand is localized to one cellular compartment.  If the 
protein is localized to the cytoplasm the ribozyme may cleave in the nucleus during or 
immediately following transcription, and if the protein is localized to the nucleus the 
ribozyme may cleave after export to the cytoplasm.  We attempted to elucidate the ligand 
localization requirements of our MS2-responsive switches in order to discover where in 
the cell the ribozyme cleaves, which in turn will inform the choice of new protein ligands 
for ribozyme switches in the future. 
For all experiments described above, we expected the ligand to be found in both 
the nucleus and the cytoplasm, as MS2 (14 kDa), MS2mut (14 kDa), and 2MS2mut (28 
kDa) are small enough to passively diffuse through the nuclear pore without the aid of 
any nuclear transport machinery29.  We attempted to control protein localization by 
creating 2MS2mut constructs with either an N-terminal nuclear localization sequence 
derived from Simian virus 40 (SV40)30 (NLS-2MS2mut) or a C-terminal nuclear export 
sequence derived from protein kinase A inhibitor α (PKIα)31 (2MS2mut-NES).  We 
transiently transfected Flp-In T-REx HEK293 cells with plasmids encoding each of these 
three 2MS2mut localization variants, induced protein ligand expression from the CMV-
TetO2 promoter using doxycycline, and harvested the total protein in nuclear and 
cytoplasmic extractions.  Immunoblotting of these extracts with an antibody specific for 
MS2 revealed that 80% of an average cell’s 2MS2mut is found in the cytoplasm, despite 
its small size (Figure 3.8A).  The NES tag localized 90% of an average cell’s 2MS2mut 
to the cytoplasm, which is comparable to the distribution of the cytoplasmic control 
protein.  Compared to the untagged version of 2MS2mut, the distribution of NLS-tagged 
protein was shifted towards the nucleus, but a significant amount remained in the 
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cytoplasm, such that the protein was present at approximately the same concentration in 
both compartments.  Immunofluorescence microscopy of stable cell lines expressing the 
three localization variants of 2MS2mut using the same anti-MS2 antibody validated the 
subcellular distribution determined by immunoblotting (Figure 3.8B). 
 
 
Figure 3.8.  Subcellular localization of ligands with and without localization signals.  (A) 
Immunoblot showing subcellular compartment distribution of 2MS2mut, NLS-2MS2mut, 
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and 2MS2mut-NES, along with nuclear and cytoplasmic controls.  Percentages are 
calculated by normalizing quantified band intensity to the number of cells harvested.  C, 
cytoplasm; N, nucleus; HDAC1, histone deacetylase 1; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase.  (B) Immunofluorescence microscopy of 2MS2mut, NLS-
2MS2mut, and 2MS2mut-NES using the same anti-MS2 antibody as in A.  Green, anti-
MS2 antibody and fluorescent secondary antibody; red, 7-aminoactinomycin D (7-AAD) 
nuclear stain. 
 
We tested the localization-tagged versions of 2MS2mut with a subset of ribozyme 
switches in both transient and stable expression assays (Figure 3.9).  While the switches 
responded similarly to 2MS2mut and 2MS2mut-NES, we observed that NLS-2MS2mut 
produced a slightly lower level of switching activity.  As we have repeatedly observed by 
flow cytometry and immunoblotting that proteins with NLS tags are present at lower 
levels than untagged versions, we inferred that the lower switching activity was likely 
due to lower protein levels and not an effect of the altered subcellular distribution of the 
protein.  Importantly, because the switches respond to 2MS2mut-NES, we concluded that 
cytoplasmic localization of the protein ligand is sufficient for switching activity, yielding 
as much as 5.3-fold ON switching with MS2-B11 and 4.3-fold OFF switching with MS2-
C1 in a stable expression assay. 
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Figure 3.9.  Activity of ribozyme switches with ligands with and without localization 
signals: 2MS2mut, NLS-2MS2mut, and 2MS2mut-NES.  (A) Relative BFP fluorescence 
levels are reported for transiently transfected constructs encoding ribozyme switch 
sequences cotransfected with a transfection control plasmid.  Reported values are 
geometric mean ± s.d. from biological duplicates and normalized to the non-cleaving 
sTRSVctrl.  (B) Relative BFP fluorescence levels are reported for stably integrated 
constructs encoding ribozyme switch sequences.  Reported values are geometric mean ± 
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s.d. from biological duplicates or triplicates and normalized to the non-cleaving 
sTRSVctrl. 
 
As our NLS-2MS2mut protein failed to fully localize to the nucleus, we created 
new constructs to achieve the desired localization.  We hypothesized that although NLS2-
2MS2mut was being actively transported into the nucleus, its small size allowed it to 
passively diffuse out of the nucleus and accumulate in the cytoplasm to a significant level 
despite the NLS.  We created 2MS2mut-DsRed fusion proteins with either an N-terminal 
NLS (NLS-2MS2mut-DsRed) or a C-terminal NES (2MS2mut-DsRed-NES), as well as 
2MS2mut-DsRed without a localization sequence.  These larger fusion proteins were 
expected to passively diffuse through the nuclear pore to a much lower extent than 
2MS2mut without DsRed, and the fluorescent tag allowed for direct MS2 detection 
without immunostaining.  We transiently transfected Flp-In T-REx HEK293 cells with 
plasmids encoding each of these three protein variants, induced MS2 expression from the 
CMV-TetO2 promoter using doxycycline, and imaged the cells using confocal 
fluorescence microscopy (Figure 3.10).  All three variants of the protein localized to the 
expected cellular locations.  The presence in these constructs of BFP, which does not 
contain a localization signal and was found in both the nucleus and the cytoplasm, 
allowed for direct comparison between this protein and DsRed.  While 2MS2mut-DsRed 
exhibited the same distribution throughout the cell as BFP, NLS-2MS2mut-DsRed was 
localized to the nucleus and 2MS2mut-DsRed-NES was localized to the cytoplasm. 
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Figure 3.10.  Confocal fluorescence microscopy of ligands with and without localization 
signals: 2MS2mut-DsRed, NLS-2MS2mut-DsRed, 2MS2mut-NES-DsRed.  Red, DsRed; 
blue, BFP; green, SYTO 16 nuclear stain.  Scale bars are 10 µm. 
 
We tested the three 2MS2mut-DsRed variants with the best ON (MS2-B11) and 
OFF (MS2-C1) switch in a stable expression assay.  As with 2MS2mut without DsRed, 
the switches responded to the nuclear-localized ligand to a lesser extent than to either the 
unlocalized or cytoplasmic-localized ligand, which yielded similar levels of response 
(MS2-B11: 3.6-fold for NLS, 6.4-fold for unlocalized, 6.5-fold for NES; MS2-C1: 2.8-
fold for NLS, 4.6-fold for unlocalized, 4.3-fold for NES) (Figure 3.11).  As described 
above, we assumed that the lower level of switch responsiveness to NLS-2MS2mut-
DsRed was likely due to lower steady-state level of protein rather than a specific effect of 
nuclear localization of ligand. 
 
!  
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Figure 3.11.  Activity of ribozyme switches with improved localized ligands: 2MS2mut-
DsRed, NLS-2MS2mut-DsRed, and 2MS2mut-DsRed-NES.  Relative BFP fluorescence 
levels are reported for stably integrated constructs encoding ribozyme switch sequences.  
Reported values are geometric mean ± s.d. from biological duplicates and normalized to 
the non-cleaving sTRSVctrl. 
 
To examine the relationship between ligand expression level and switch response 
for the three localization variants of 2MS2mut-DsRed, we measured BFP regulation 
activity over a range of ligand inducer concentrations in a stable expression assay (Figure 
3.12A).  MS2-B11 and MS2-C1 exhibited a lower response to NLS-2MS2mut-DsRed 
than the other two ligand variants at all doxycycline concentrations tested.  However, 
comparing BFP regulation activity to DsRed fluorescence (Figure 3.12B) reveals that all 
three protein variants yield similar switch activity at a given level of DsRed fluorescence.  
From these results we concluded that switch response is dependent on ligand expression 
level and not on its localization, and that nuclear and cytoplasmic localization of ligand 
are each sufficient for switching activity. 
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Figure 3.12.  Activity of ribozyme switches with improved localized ligands over a range 
of ligand concentrations.  (A) Reporter gene expression as a function of doxycycline 
concentration.  Relative BFP fluorescence levels are reported for stably integrated 
constructs encoding ribozyme switch sequences.  Reported values are geometric mean ± 
s.d. from biological duplicates and normalized to the non-cleaving sTRSVctrl.  (B) 
Reporter gene expression as a function of DsRed fluorescence.  The same data sets in B 
are plotted against DsRed fluorescence levels.  Relative BFP and DsRed fluorescence 
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levels are reported for stably integrated constructs encoding ribozyme switch sequences.  
Reported values are geometric mean ± s.d. from biological duplicates and BFP values are 
normalized to the non-cleaving sTRSVctrl. 
 
 
Development of ribozyme switch platforms responsive to additional proteins 
We attempted to demonstrate the flexibility of our ribozyme switch platform by 
creating devices responsive to additional proteins.  We chose two other bacteriophage 
proteins with demonstrated sequence-specific RNA binding, Pseudomonas phage PP7 
coat protein32 and the 1–22 peptide of lambda N protein22,33.  We also chose nuclear 
factor κB (NF-κB) and β-catenin, two endogenous proteins involved in transcription and 
deregulated in many forms of cancer7,34–38.  Aptamers to each of these proteins have been 
selected using SELEX and validated for in vivo function39–42.  
We designed three ribozyme switches containing the PP7 aptamer (Figure 3.13A).  
They are based on MS2-C3, which showed a high level of response to MS2, with the PP7 
aptamer replacing the MS2 aptamer.  The three designs differ from each other in the 
length of the aptamer stem beyond bulge II.  Experiments were performed with transient 
expression assays using the improved characterization system (Figure 3.2), with the 
protein ligand expressed from the CMV-TetO2 promoter.  We used a mutant version of 
PP7 containing amino acid substitutions C68A and C71A to reduce multimerization 
while maintaining RNA binding affinity43, similar to our strategy with the MS2 ligand.  
The data demonstrate little gene knockdown and no switching activity for any of the PP7 
designs (Figure 3.13B). 
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Figure 3.13.  Design and testing of PP7-responsive switch designs.  (A) Structures of the 
three designs.  Coloring is the same as in Figure 3.1.  (B) Activity of PP7-responsive 
switch designs.  Relative BFP fluorescence levels are reported for transiently transfected 
constructs encoding ribozyme switch sequences cotransfected with a transfection control 
plasmid.  Reported values are geometric mean ± s.d. from biological duplicates and 
normalized to the non-cleaving sTRSVctrl. 
 
We designed four ribozyme switches containing the lambda N aptamer (Figure 
3.14A).  Lambda-1 is based on the previously characterized theophylline-responsive 
L2b811 and Lambda-2 is based on MS2-B11, with the lambda N aptamer replacing the 
theophylline and MS2 aptamers, respectively.  The other two designs do not contain a 
transmitter component, and loop II is replaced by the lambda N aptamer loop in a similar 
fashion as the MS2-C designs (Figure 3.1).  Experiments were performed with transient 
expression assays using the improved characterization system (Figure 3.2), with the 
protein ligand expressed from the CMV-TetO2 promoter.  The data demonstrate that the 
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four ribozyme switch designs exhibit a range of gene knockdown activity; however, none 
respond to lambda N (Figure 3.14B). 
 
 
Figure 3.14.  Design and testing of lambda-N-responsive switch designs.  (A) Structures 
of the four designs.  Coloring is the same as in Figure 3.1.  (B) Activity of lambda-N-
responsive switch designs.  Relative BFP fluorescence levels are reported for transiently 
transfected constructs encoding ribozyme switch sequences.  Reported values are 
geometric mean ± s.d. from biological duplicates and normalized to the non-cleaving 
sTRSVctrl. 
 
We designed thirteen ribozyme switches containing the aptamer for the p50 
subunit of NF-κB and five ribozyme switches containing the aptamer for the p65 subunit 
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(Figure 3.16A).  These designs all contain transmitter components, similar to the MS2-B 
designs (Figure 3.1), differing from each other in the sequence identity of loop I and the 
transmitter.  For each ligand we designed both ON and OFF switches. 
 
 
Figure 3.15.  NF-κB-responsive ribozyme switch characterization system.  (A) A 
fluorescent reporter (BFP) with ribozyme switch is encoded on a plasmid, which is 
transfected into a Flp-In T-REx HEK293 cell line.  The NF-κB signaling pathway is 
induced with the addition of TNFα, LPS, or LPS in combination with cycloheximide.  (B) 
The switch plasmid is cotransfected with a plasmid encoding the protein ligand (under 
the control of CMV-TetO2) and a fluorescent transfection marker.  Addition of 
doxycycline derepresses the CMV-TetO2 promoter, turning on expression of the ligand, 
which regulates the activity of ON and OFF switches.  Cotransfections were also 
performed in conjunction with LPS induction. 
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We employed several different strategies in attempting to elicit switch response to 
NF-κB ligand.  The NF-κB p50/p65 heterodimer is normally bound to the inhibitor IκB, 
which blocks its NLS, preventing import into the nucleus44.  Upon activation of the NF-
κB pathway, IκB is targeted for ubiquitin-dependent degradation, releasing NF-κB to 
translocate into the nucleus and activate transcription of its target genes34.  It is expected 
that NF-κB will not bind to its aptamer when inhibited, as IκB stabilizes NF-κB in a 
conformation with very weak nucleic acid affinity45–47.  After transfecting Flp-In T-REx 
HEK293 cells with plasmids encoding our switches, we activated the NF-κB pathway 
with tumor necrosis factor α (TNFα), lipopolysaccharide (LPS), or LPS in combination 
with cycloheximide (Figure 3.15).  We also tried expressing p50 and p65 heterologously, 
in cotransfections of a plasmid encoding the protein and a plasmid encoding a cognate 
switch.  Finally, we tried heterologous protein expression in combination with LPS 
induction.  Although the designs exhibited a range of gene knockdown activity, none of 
them displayed switching activity under any of the conditions tested (Figure 3.16B). 
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Figure 3.16.  Design and testing of NF-κB-responsive switch designs.  (A) ON and OFF 
switches were designed with aptamers for p50 and p65 subunits of NF-κB.  Coloring is 
the same as in Figure 3.1.  See Supplementary Table 3.1 for sequences.  (B) Activity of 
NF-κB-responsive switch designs.  Relative BFP fluorescence levels are reported for 
transiently transfected constructs encoding ribozyme switch sequences cotransfected with 
a plasmid encoding p50 or p65 and a fluorescent transfection control.  Reported values 
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are geometric mean ± s.d. from biological duplicates and normalized to the non-cleaving 
sTRSVctrl. 
 
We designed two sets of ribozyme switches containing the β-catenin aptamer 
(Figure 3.17A).  In one set of designs (Bcat-A) the β-catenin aptamer replaced loop I of 
four different hammerhead ribozymes similar in sequence and structure to sTRSV 
(sLTSV−, sLTSV+, CChMVd−, and SCMoV+), following a similar strategy as the MS2-
C designs.  The other set of designs (Bcat-B) was similar to the MS2-responsive 
sequential aptamer and ribozyme designs (MS2-D), with the β-catenin aptamer just 
upstream of the ribozyme.  These six designs varied in the length and sequence identity 
of the transmitter component. 
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Figure 3.17.  Design and testing of β-catenin-responsive switch designs.  (A) β-catenin-
responsive loop I replacement (Bcat-A) and sequential aptamer and ribozyme (Bcat-B) 
switch designs.  Coloring is the same as in Figure 3.1.  See Supplementary Table 3.1 for 
sequences.  (B) Activity of β-catenin-responsive switch designs in a transient expression 
assay.  Relative BFP fluorescence levels are reported for transiently transfected 
constructs encoding ribozyme switch sequences.  Reported values are geometric mean ± 
s.d. from biological duplicates and normalized to the non-cleaving sTRSVctrl.  (C) 
Activity of β-catenin-responsive switch designs in a transient expression assay with 
transfection control.  Relative BFP fluorescence levels are reported for transiently 
transfected constructs encoding ribozyme switch sequences cotransfected with a 
transfection control plasmid.  Reported values are geometric mean ± s.d. from biological 
duplicates and normalized to the non-cleaving sTRSVctrl. 
 
β-catenin translocates into the nucleus upon activation of the Wnt signaling 
pathway, and in the absence of signaling is phosphorylated and degraded by the 
proteasome38.  After transfecting Flp-In T-REx HEK293 cells with plasmids encoding 
our switches, we activated the pathway with the addition of the cytokine Wnt3A to the 
cell culture media but observed no switch response.  We also tried heterologously 
expressing the Arm 1–12 domain of β-catenin48, which has been shown to have higher 
affinity for the aptamer than the full-length protein49, from the CMV-TetO2 promoter in a 
transient transfection assay, as we did with the MS2 proteins (Figure 3.2).  Most of the 
loop I replacement designs (Bcat-A) exhibited little gene knockdown activity, while the 
sequential designs (Bcat-B) exhibited high levels of gene knockdown activity, similar to 
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the MS2-D designs (Figure 3.17B).  Only one design, Bcat-A4, exhibited responsiveness 
to heterologous β-catenin in this experimental system.  Induction with Wnt3A in addition 
to the heterologous expression of β-catenin had no effect on switch activity.  We 
reexamined four switch designs in an assay with a transfection control plasmid and Bcat-
A4 exhibited 1.3-fold OFF-switching (Figure 3.17C).  Stable integration of the Bcat-A4 
and heterologous β-catenin construct into Flp-In T-REx HEK293 cells resulted in no 
switch response, likely due to the ligand being expressed at a lower level than in transient 
transfections, as described above (Figure 3.5). 
 
 
Discussion 
We developed protein-responsive gene-regulatory devices based on the ribozyme 
switch platform previously developed in the Smolke laboratory11.  We first screened a 
large number of designs with different architectures, and found that directed 
conformational changes of ribozyme structure are important for ligand responsiveness.  
Specifically, coupling the MS2 aptamer directly to a ribozyme loop, without a transmitter 
component (MS2-A), resulted in devices that did not respond to MS2 ligand.  Designs 
containing a transmitter that altered the structure of the stem and catalytic core (MS2-B), 
analogous to previously developed ribozyme switches11, were among the most highly 
functional switch designs tested.  The designs containing a transmitter that altered the 
structure of the stem and loop (MS2-C) also led to functional switches.  Three transmitter 
designs, MS2-B1, MS2-B3, and MS2-B7, were altered by replacing loop I with an 
alternative sequence, generating MS2-B2, MS2-B10, and MS2-B11.  In all three cases 
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the altered loop resulted in improved gene knockdown and switching activity (Figure 
3.7B).  The sequential designs, with the aptamer immediately upstream of the ribozyme 
in the transcript (MS2-D), were mostly insensitive to ligand but one (MS2-D5) exhibited 
a moderate amount of switching activity (up to 2.4-fold) and the lowest basal expression 
level of all designs tested, with gene knockdown activity comparable to wild-type 
ribozyme (sTRSV). 
We further improved our characterization system by optimizing the MS2 ligand.  
Responsiveness to wild-type MS2 in our initial switch characterization study was at most 
1.8-fold (Figure 3.4, MS2-B2).  Replacing wild-type MS2 with a mutant containing two 
amino acid substitutions that prevent multimerization27 improved sensitivity for most of 
the switches tested (Figure 3.7A).  The fused dimer of this mutant MS2 elicited an even 
greater switch response, including from MS2-B1, which was unresponsive to the wild-
type and mutant monomer (Figure 3.7A).  We concluded that the fused dimer of mutant 
MS2 was the best ligand for characterizing our switch designs. 
Using our optimized ligand we were able to demonstrate high levels of ON-
switching with MS2-B11 (up to 4.1-fold) and OFF-switching with MS2-C1 (up to 3.8-
fold).  In contrast, previously described small-molecule-responsive ribozyme switches 
from the Smolke laboratory15,17 have exhibited at most 2.1-fold ON switching (L2b18tc, 
tetracycline-responsive) and 1.7-fold OFF-switching (Lb2OFF, theophylline-responsive) 
in human cell lines.  Switching activity was improved by incorporating multiple copies of 
the ribozyme switch into the 3’ UTR of the target gene, resulting in up to 3.5-fold ON-
switching (L2b8, 2 copies and L2b9, 3 copies)17.  However, OFF switch activity has not 
been improved by this method. 
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We demonstrated the localization requirements of our ribozyme switches by 
assaying for sensitivity to our optimized ligand with fused localization signals.  The 
initial implementation of these localization signals did not fully direct the protein to the 
desired subcellular compartment (Figure 3.8).  Although the NES-tagged protein was 
present in the nucleus at levels no higher than a cytoplasmic control protein, the NLS-
tagged protein was present in both the nucleus and the cytoplasm.  We hypothesized that 
despite the fusion with localization signals the protein was passively diffusing through 
the nuclear pore due to its small size.  We therefore created fusion proteins with DsRed, 
whose increased size was predicted to prevent passive diffusion through the nuclear pore 
and result in full localization, which was verified with confocal fluorescence microscopy 
(Figure 3.10). 
Testing of localized variants of 2MS2mut-DsRed with MS2-B11 and MS2-C1 
revealed little dependence of switch activity on ligand localization.  Unlocalized and 
cytoplasmic-localized ligands elicited similar levels of response for each switch, while 
the nuclear-localized ligand elicited much lower levels of response (Figure 3.11).  We 
have observed by flow cytometry that NLS-tagged fluorescent proteins generate 
fluorescence levels less than half those of analogous untagged proteins (Figure 3.12B and 
Ryan Bloom, unpublished results).  It is possible that the addition of the seven-amino-
acid NLS to the N-terminus of a fluorescent protein affects its three-dimensional structure 
in a way that negatively impacts its fluorescent output; however, we believe this is 
unlikely.  Immunoblotting indicates that the total amount of MS2 protein per cell is lower 
with the NLS tag than without (Figure 3.8A), suggesting that the lower level of 
fluorescence observed from NLS-tagged proteins is due to lower steady-state protein 
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levels and not to a decrease in fluorescence output per molecule.  This conclusion is 
further supported by our finding that switch response is dependent on ligand expression 
level as measured by fluorescence (Figure 3.12B).  Assuming that each of the three 
localization variants of 2MS2mut-DsRed exhibits roughly the same fluorescence output 
per molecule, the data show that switch response is correlated with ligand expression 
level regardless of localization. 
Nuclear and cytoplasmic localization of ligand each appear to be sufficient for 
switching activity in human cells.  This is somewhat surprising for an ON switch such as 
MS2-B11, which cleaves in the absence of ligand.  One might expect this switch to 
cleave during or immediately after transcription if ligand is absent from the nucleus, or to 
cleave after nuclear export if ligand is absent from the cytoplasm.  However, our data did 
not support these initial expectations. 
Although our confocal fluorescence microscopy measurements show clear 
localization, we cannot rule out the possibility that a small amount of the NLS-tagged 
ligand is found in the cytoplasm and a small amount of the NES-tagged ligand is found in 
the nucleus.  The presence of such mislocalized protein could prevent precise 
examination of the effect of ligand localization on ribozyme switch activity if that small 
amount were sufficient to prevent ribozyme ON switch cleavage.  However, the 
correlation between switch response and DsRed fluorescence (Figure 3.12B) suggests 
that this is unlikely.  If, for example, nuclear localization were necessary for switch 
activity, and switches appeared to respond to NES-tagged ligand, we would expect the 
required amount of NES-tagged ligand expression to be much higher than NLS-tagged 
ligand to yield the same level of switch activity, as most of the NES-tagged protein would 
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be in the cytoplasm and unable to affect the switch.  We observed that similar ligand 
expression levels, as measured by fluorescence, resulted in similar levels of switching 
regardless of localization signal. 
Our data suggest that the ribozyme switches do not cleave before nuclear export 
to a significant degree, nor do they cleave in the cytoplasm to a significant degree when 
the ligand is present in the nucleus.  We speculate that ribozyme cleavage in the nucleus 
is low, possibly due to prevention of proper folding by binding of proteins that form the 
messenger ribonucleoprotein (mRNP).  This would minimize ribozyme cleavage before 
the switch is exposed to cytoplasmic-localized ligand.  When ligand is localized to the 
nucleus, we speculate that it is able to bind to the aptamer and is carried out of the 
nucleus by the mRNA during nuclear export.  The ability of mRNA containing an 
aptamer to carry MS2 out of the nucleus has been previously demonstrated20, but this 
behavior may depend on the small size of the MS2 protein and not be generalizable to 
larger proteins.  After export to the cytoplasm, dissociation of the ligand from the 
ribozyme switch would be favored due to the extremely low local concentration of free 
ligand.  A low ligand off-rate and a low ribozyme cleavage rate would both contribute to 
allowing the mRNA to be translated before cleavage.  Functional MS2-responsive 
ribozyme switches presented here exhibit off rate constants in the range of 0.001–0.05 s−1 
(Andrew Kennedy, unpublished results) and cleavage rate constants in the range of 0.05–
1 min−1 (Andrew Kennedy, unpublished results).  ON switches with higher cleavage rates 
would be expected to be less responsive to localized ligand (nuclear or cytoplasmic), and 
ON switches with higher ligand off-rates would be expected to be less responsive to 
nuclear-localized ligand. 
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In the future the ribozyme switch mechanism of action could be more thoroughly 
investigated.  Studies using switches with a range of cleavage-rate constants and ligand 
off-rate constants would establish the relationship between these parameters and in vivo 
response to localized ligands.  This in turn would confirm or disprove our supposition 
that nuclear and cytoplasmic localization are each sufficient for switching activity.  If it is 
indeed true that ligand localization does not negatively impact switching activity, then 
our ribozyme switch platform would be capable of sensing proteins in the nucleus or the 
cytoplasm.  In contrast, switches based on regulation of shRNA processing9 or splicing10 
are limited to sensing cytoplasmic or nuclear proteins, respectively. 
We attempted to develop ribozyme switches responsive to additional proteins.  
We suspected that generating switches with aptamers for bacteriophage proteins (PP7 and 
lambda N) would be straightforward, basing our designs on functional MS2-responsive 
switches.  However, none of these designs responded to ligand.  We next attempted to 
generate ribozyme switches responsive to NF-κB and β-catenin, two proteins involved in 
transcription and deregulated in many forms of cancer7,34–37, for which there exist in vitro 
selected aptamers with validated in vivo function39–42.  Although NF-κB and β-catenin 
are endogenously expressed in our human cell line, we did not expect them to be 
available for binding to ribozyme switches without activation of their signaling pathways 
or heterologous overexpression.  We were unable to demonstrate NF-κB-responsiveness, 
but one β-catenin switch, Bcat-A4, exhibited 1.3-fold OFF-switching in response to 
transient heterologous expression of β-catenin.  We suspect that Bcat-A4 did not respond 
to endogenous or stably expressed β-catenin because the steady-state levels of protein 
were too low.  In the future high-throughput in vivo screening methods50–52 could be used 
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to assay large libraries of devices to explore a wider design space and achieve greater 
success generating functional switches responsive to new protein ligands. 
The protein-responsive ribozyme switch platform we have developed is unique in 
its ability to respond to ligands in both the nucleus and the cytoplasm, while previously 
reported protein-responsive switches can function in only one compartment9,10,53,54.  One 
potential limitation of our platform is that it is not able to detect changes in protein 
localization.  However, our platform’s capability of sensing both nuclear and cytoplasmic 
proteins may be an important advantage for its use as a noninvasive reporter or 
phenotypic controller in future applications. 
 
 
Methods 
Plasmid construction 
All plasmids were constructed using standard molecular biology techniques.  
Oligonucleotides were synthesized by Integrated DNA Technologies and the Stanford 
Protein and Nucleic Acid Facility.  Cloning enzymes, including restriction enzymes and 
T4 DNA ligase, were obtained from New England Biolabs.  Ligation products were 
electroporated into Escherichia coli DH10B (Life Technologies) using a GenePulser XP 
(Bio-Rad Laboratories) system or transformed into E. coli One Shot Top 10 (Life 
Technologies) using standard methods.  Clones were screened using colony polymerase 
chain reaction (PCR) and verified by sequencing (Elim Biopharmaceuticals).  15% 
glycerol stocks were made from E. coli in logarithmic growth phase and stored at −80°C. 
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A standardized cloning method was developed to facilitate insertion of ligand-
responsive devices and ligand coding regions into a single plasmid backbone.  A DNA 
fragment encoding d2EGFP with a bGHpA signal and the CMV-TetO2 promoter was 
synthesized by GeneArt (Life Technologies) and inserted into pcDNA5/FRT (Life 
Technologies) between the restriction sites AflII/KpnI to form pCS2304 (Figure 3.18), 
which contained a CMV promoter expressing d2EGFP and FRT recombinase sites 
compatible with stable integration into the genome of Flp-In T-REx HEK293 cells (Life 
Technologies) to create isogenic stable cell lines.  The coding region of the fusion protein 
MS2-DsRedMonomer was PCR amplified from pCS1392 (courtesy Stephanie Culler) 
using the primers No NLS A/X Fwd and DsRed A/X Rev and inserted into pCS2304 
between XhoI/ApaI to form pCS2359.  MS2-responsive ribozyme switch designs were 
inserted into pCS2359 between AvrII/AscI. 
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12 BglII (1)
1769 AscI (1)
CMV TetO2 2059..2696
2697 KpnI (1)
2758 NotI (1)
2765 XhoI (1)
2777 ApaI (1)
bGHpA 2808..3032
FRT 3316..3363
SV40 4523..4653
HygroR 3371..4391
pUC 5709..5036
Ampicillin 6714..5854
Bla 6813..6715
pCS2304
6850 bp
CMV 232..819
908 AflII (1)
d2EGFP 914..1759
1760 AvrII (1)
bGHpA 1802..2027
bGHpA 1314..1539
1281 AscI (1)
1272 AvrII (1)
BFP 570..1271
553 XhoI (2)
EF1a 18..552
12 BglII (1)
CMV TetO2 1571..2208
2209 KpnI (1)
2270 NotI (1)
2277 XhoI (2)
MS2 2283..2678
2683 ApaI (1)
bGHpA 2714..2938
FRT 3222..3269
SV40 4429..4559
HygroR 3277..4297
pUC 5615..4942
Ampicillin 6620..5760
Bla 6719..6621
pCS2595
6756 bp
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Figure 3.18.  Plasmid maps. 
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Ampicillin 6231..5371
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pCS2397
6367 bp
553 XhoI (1)
BFP 570..1271
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An Ef1α promoter with the coding region of BFP was PCR amplified from 
pCS2585 (courtesy Melina Mathur) using the primers EF1BFP Fwd and EF1BFP Rev 
and inserted between BglII/AvrII, and the coding region of MS2 was PCR amplified from 
pCS1392 using No NLS A/X Fwd and MS2 A/X Rev and inserted between XhoI/ApaI 
into pCS2304 to form pCS2595 (Figure 3.18).  MS2-responsive ribozyme switch designs 
were inserted into pCS2595 between AvrII/AscI. 
The plasmid pCS2359 was digested with NheI/AvrII to remove d2EGFP and 
ligated to form pCS2406.  The coding region of MS2 was PCR amplified from pCS1392 
using the primers No NLS A/X Fwd and MS2 A/X Rev and inserted into pCS2406 
between XhoI/ApaI to form pCS2409. 
The coding region of MS2mut (V75E/A81G) was PCR amplified from the MBP-
MS2-His plasmid (courtesy Rachel Green, Department of Molecular Biology and 
Genetics, Johns Hopkins University) using the primers MS2 NotI F and MS2 ApaI R and 
inserted into pCS2595 between NotI/ApaI to form pCS2631.  MS2-responsive ribozyme 
switch designs were inserted into pCS2631 between AvrII/AscI. 
A DNA fragment encoding 2MS2mut (MS2 V75E/A81G head-to-tail fused 
dimer) was synthesized by GeneArt (Life Technologies) and inserted into pCS2595 
between NotI/ApaI to form pCS2686.  The coding region of 2MS2mut was PCR 
amplified from pCS2686 using the primers NLS MS2 F and 2MS2mut R to add an N-
terminal NLS, and using the primers 2MS2mut F and NES MS2 R to add a C-terminal 
NES, and inserted into pCS2595 between NotI/ApaI to form pCS2747 and pCS2787, 
respectively.  MS2-responsive ribozyme switch designs were inserted into pCS2686, 
pCS2747, and pCS2787 between AvrII/AscI. 
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The coding region of DsRedMonomer was PCR amplified from pCS2359 using 
the primers DsRed GF and DsRed GR, and using the primers DsRed GF and DsRed NES 
R to add a C-terminal NES.  The resulting DNA fragments were inserted into plasmids 
digested with ApaI using Gibson assembly55 as follows: DsRed into pCS2686 to form 
pCS2897, DsRed into pCS2747 to form pCS2902, and DsRed-NES into pCS2686 to 
form pCS2907.  MS2-responsive ribozyme switch designs were inserted into pCS2897, 
pCS2902, and pCS2907 between AvrII/AscI. 
The coding region of Clover GFP was PCR amplified from pCS2586 (courtesy 
Melina Mathur) using the primers GF Clover and GR Clover, and pCS2595 was PCR 
amplified using the primers GF EF1 and GR EF1.  The resulting DNA fragments were 
assembled using Gibson assembly55 to form pCS2391 (Figure 3.18), which contained 
Clover GFP in place of BFP. 
The coding region of the PP7 coat protein was PCR amplified from Addgene 
plasmid 28174 (Kathleen Collins) using the primers PP7 NotI F and PP7 ApaI R and 
inserted into pCS2595 between NotI/ApaI to form pCS2847.  PP7-responsive ribozyme 
switch designs were inserted into pCS2847 between AvrII/AscI. 
The DNA fragment lambda N was inserted into pCS2595 between NotI/ApaI to 
form pCS2816.  Lambda-N-responsive ribozyme switch designs were inserted into 
pCS2816 between AvrII/AscI. 
The DNA fragment insertNA was inserted into pCS2595 between NotI/ApaI to 
form pCS2397 (Figure 3.18).  NF-κB-responsive ribozyme switch designs were inserted 
into pCS2397 between AvrII/AscI.  The coding region of NF-κB p50 was PCR amplified 
from pCS1806 (courtesy Stephanie Culler) using the primers p50 NotI F and p50 ApaI R 
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and inserted into pCS2391 between NotI/ApaI to form pCS2604.  The coding region of 
NF-κB p65 was PCR amplified from pJ1448 (courtesy Louis Maher III, Department of 
Biochemistry and Molecular Biology, Mayo Clinic College of Medicine) using the 
primers p65 NotI F and p65 ApaI R and inserted into pCS2391 between NotI/ApaI to 
form pCS2605. 
β-catenin-responsive ribozyme switch designs were inserted into pCS2397 
between AvrII/AscI.  The coding region of β-catenin Arm 1–12 was PCR amplified from 
Addgene plasmid 17198 (Randall Moon) using the primers b-cat NotI F and b-cat ApaI R 
and inserted into pCS2595 between NotI/ApaI to form pCS2824.  β-catenin-responsive 
ribozyme switch designs were inserted into pCS2824 between AvrII/AscI. 
 
Human cell culture 
Flp-In T-REx HEK293 cells (Life Technologies) were cultured in 10 mL (10 cm 
dish) or 3 mL (6 cm dish) Dulbecco's Modified Eagle's medium (DMEM) (Life 
Technologies) supplemented with 10% fetal bovine serum (FBS) (Life Technologies), 
100 mg/L zeocin (Life Technologies), and 5 mg/L blasticidin (Life Technologies) in a 
humidified incubator at 37°C and 5% CO2.  Cells were seeded at 2x104 cells/mL and 
passaged regularly using 0.25% trypsin-EDTA (Life Technologies), with media replaced 
every 48–72 hours.  Cells stably integrated with Flp-In constructs were cultured similarly, 
except the cell culture media were supplemented with 100 mg/L hygromycin B (Life 
Technologies) and no zeocin. 
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Stable cell line generation 
Flp-In T-REx HEK293 cells were seeded at 1x105 cells/mL in 2 mL (6-well plate) 
DMEM with 10% FBS.  24 hours later the cells were cotransfected with a pcDNA5/FRT-
derived plasmid and pOG44 (Life Technologies) in a 1:9 ratio using FuGENE HD 
(Promega) according to the manufacturer’s instructions.  Typically DNA and FuGENE 
were incubated together in Opti-MEM in a 1:3:50 (g:L:L) ratio for approximately 1 hour, 
with 2 mL samples receiving 2 µg of DNA.  24 hours after transfection the cells were 
resuspended using 0.25% trypsin-EDTA and DMEM with 10% FBS, and ¼ of the cells 
were used to seed 2 mL (6-well plate) DMEM with 10% FBS.  24 hours later the media 
were replaced with DMEM with 10% FBS, 200 mg/L hygromycin B, and 5 mg/L 
blasticidin.  The media were replaced every 72–96 hours until macroscopic colonies were 
visible, usually after 10–14 days.  Colonies were pooled together with 0.25% trypsin-
EDTA and passaged into DMEM with 10% FBS, 100 mg/L hygromycin B, and 5 mg/L 
blasticidin.  10% dimethyl sulfoxide (DMSO) stocks were made from resuspended cells, 
cooled by 1 degree/minute to −80°C, then stored at −320°C. 
 
Transient transfection 
Flp-In T-REx HEK293 cells were seeded at 1x105 cells/mL in 500 µL (24-well 
plate), 10 mL (10 cm dish), or 400 µL (8-chambered coverglass) DMEM with 10% FBS.  
21–27 hours (flow cytometry assay) or 48 hours (cellular fractionation and extraction) or 
24 hours (confocal microscopy) after seeding the cells were transfected with one or two 
plasmids using FuGENE HD (Promega) or Lipofectamine 2000 (Life Technologies) 
according to the manufacturer’s instructions.  Typically DNA and FuGENE HD were 
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incubated together in Opti-MEM in a 1:3:50 (g:L:L) ratio for 1 approximately hour, while 
DNA and Lipofectamine were incubated together in Opti-MEM in a 1:2:100 (g:L:L) ratio 
for 5 minutes.  With either transfection reagent, 500 µL samples received 500 ng of 
DNA, 10 mL samples received 10 µg of DNA, and 400 µL samples received 400 ng of 
DNA. 
 
Flow cytometry 
18–28 hours after seeding (30–75 minutes after transfection if applicable) 
doxycycline was added to derepress the CMV-TetO2 promoter.  24–26 hours after 
transfection with plasmids encoding NF-κB- or β-catenin-responsive ribozyme switch 
designs inducer molecules were added.  10 µg/L TNFα (Sigma-Aldrich), 500 µg/L LPS 
(Sigma-Aldrich), or 500 µg/L LPS in combination with 10 mg/L cycloheximide (Sigma-
Aldrich) were used to induce the NF-κB pathway, and 200 µg/L Wnt3A (R&D Systems) 
was used to induce the Wnt pathway.  42-52 hours after transfection fluorescence data 
were obtained by flow cytometry using the MACSQuant VYB equipped with 405 nm, 
488 nm, and 561 nm lasers (Miltenyi Biotec).  Viability was gated by side scatter and 
electronic volume, and viable cells were further gated for either DsRed, GFP, or BFP 
expression, which served as transfection controls.  DsRed, GFP, and BFP fluorescence 
was measured through 615/20 nm, 525/50 nm, and 450/50 nm band-pass filters, 
respectively.  Data were analyzed using FlowJo (Tree Star Inc.).  Geometric mean values 
from biological replicates were reported with an error range of ±1 standard deviation.  
Geometric mean fluorescence values were normalized to those of a control with no 
ribozyme or the inactive ribozyme sTRSVctrl. 
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Cellular fractionation and extraction 
1–1.5 hours before transfection cell culture media were replaced with media 
containing 1 mg/L doxycycline to derepress the CMV-TetO2 promoter.  50 hours later 
cytoplasmic and nuclear extracts were prepared using the CelLytic NuCLEAR Extraction 
Kit (Sigma) with isotonic lysis buffer and IGEPAL CA-630 detergent according to the 
manufacturer’s instructions, although modifications were made to the protocol to 
minimize cross-contamination between the nuclear and cytoplasmic fractions.  Briefly, 
cells were washed with PBS, scraped off of the culture dishes, and centrifuged at 500 x g 
for 5 minutes.  Packed cells were resuspended in isotonic lysis buffer and incubated for 1 
minute on ice, then incubated with IGEPAL CA-630 at a final concentration of 0.04% on 
ice for 3 minutes.  Lysed cells were centrifuged at 5000 x g for 30 seconds and the 
cytoplasmic fraction (supernatant) was collected.  The pelleted nuclei were washed with 
isotonic lysis buffer and 0.04% IGEPAL CA-630, then centrifuged at 5000 x g for 30 
seconds.  The pelleted nuclei were resuspended in extraction buffer and agitated at 4°C 
for 30 minutes.  Lysed nuclei were centrifuged at 18000 x g for 10 minutes and the 
nuclear fraction (supernatant) was collected. 
 
Immunoblotting 
A standard Bradford assay using Protein Assay reagent (Bio-Rad Laboratories) 
was performed with a BSA standard to determine protein concentrations.  Samples were 
run on NuPAGE 4–12% Bis-Tris Gels (Life Technologies) in NuPAGE MOPS buffer 
(Life Technologies) at 150 V for 1 hour.  Transfer was performed with extra thick blot 
paper (Bio-Rad Laboratories) and 0.45 µm Protran nitrocellulose transfer membrane 
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(Whatman) in 2x NuPAGE transfer buffer (Life Technologies) and 20% methanol using a 
Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad Laboratories) at 15 V for 15 minutes.  
Membranes were blocked with TBST (20 mM Tris, 137 mM sodium chloride, 0.1% 
Tween-20) and 5% bovine serum albumin (BSA) (Calbiochem) at room temperature for 1 
hour, then rinsed with TBST twice for 5 minutes each.  Membranes were probed with 
rabbit anti-enterobacteriophage MS2 coat protein, anti-GAPDH, and anti-HDAC1 
polyclonal antibodies (Millipore) in TBST and 1% BSA at 4°C for 16 hours, then rinsed 
with TBST twice for 5 minutes each.  Membranes were probed with sheep anti-rabbit 
IgG, horseradish peroxidase (HRP) conjugate polyclonal antibody (Millipore) at room 
temperature for 1 hour, then rinsed with TBST twice for 5 minutes each.  HRP signal was 
detected using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) 
according to the manufacturer’s instructions and a G:Box Chemi XT4 imaging system 
(Syngene).  Band intensity was calculated with GeneTools software (Syngene). 
 
Immunofluorescence microscopy 
Flp-In T-REx HEK293 cells with stably integrated 2MS2mut constructs were 
seeded at 1x105 cells/mL in 1 mL (4-chambered coverglass) DMEM with 10% FBS, 100 
mg/L hygromycin B, and 1 mg/L doxycycline to derepress the CMV-TetO2 promoter.  
Approximately 43 hours after seeding cells were washed with phosphate buffered saline 
(PBS) (Life Technologies) and fixed for 15–20 minutes using HistoChoice MB tissue 
fixative (AMRESCO).  Cells were washed twice with PBS, blocked with PBS and 1.5% 
BSA for 1 hour, and washed with PBS for 5 minutes.  Cells were probed with rabbit anti-
enterobacteriophage MS2 coat protein at 4°C for approximately 17 hours, then washed 
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with PBS for 5 minutes.  Cells were probed with sheep anti-rabbit fluorescein conjugated 
[F(ab’)2 fragments] polyclonal antibody (Chemicon) for 30 minutes, then washed thrice 
with PBS for 5 minutes each.  Cell nuclei were counterstained using 250 µg/L 7-AAD 
(Life Technologies) in PBS for 5 minutes, then washed with PBS.  Cells were imaged on 
a Zeiss Axiovert 200M fluorescence microscope (Zeiss) with a 20x objective using the 
AxioVision software (Zeiss).  Images were exported and brightness and contrast were 
adjusted using FIIJ. 
 
Confocal fluorescence microscopy 
Approximately 30 minutes after transfection 1 mg/L doxycycline was added to 
derepress the CMV-TetO2 promoter, and 23 hours later media were replaced with media 
containing 1 mg/L doxycycline.  24 hours later cell nuclei were counterstained using 250 
nM SYTO 16 (Life Technologies).  24 hours after counterstaining cells were imaged on a 
Leica TCS SP8 confocal microscope (Leica Microsystems) with a 20x objective using the 
Leica Application Suite Advanced Fluorescence software (Leica Microsystems).  Images 
were exported and brightness and contrast were adjusted using FIIJ. 
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Supplementary Tables 
Supplementary Table 3.1.  DNA sequences of RNA devices. 
RNA device ligand DNA sequence 
sTRSV N/A GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGC 
sTRSVctrl N/A GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTGAGGACAAAACAGC 
MS2-A1 MS2 coat protein 
GCTGTCACCGGACTACACCATCAGGGTAGTGTGC
TTTCCGGTCTGATGAGTCCGTGAGGACGAAACAG
C 
MS2-A2 MS2 
GCTGTCACCGGATGTGCGTACACCATCAGGGTAC
TTTCCGGTCTGATGAGTCCGTGAGGACGAAACAG
C 
MS2-A3 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTCGTACACCATCAGGGTACGGAGGACGAAA
CAGC 
MS2-A4 MS2 
GCTGTCACCGGATGTGGTTTCCGGTCTGATGAGT
CCGTCGTACACCATCAGGGTACGGAGGACGAAA
CAGC 
MS2-A5 MS2 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTCGTACACCATCAGGGTACGGAGGACGAAA
CAGC 
MS2-A6 MS2 
GCTGTCACCGGATTCGGGATCCGGTCTGATGAGT
CCGTCGTACACCATCAGGGTACGGAGGACGAAA
CAGC 
MS2-A7 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTGCGTACACCATCAGGGTACGAGGACGAAA
CAGC 
MS2-B1 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTGTCCAGGATCACCGGACGGGACGGAGGA
CGAAACAGC 
MS2-B2 MS2 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGTCCACCATCAGGGGACGGGACGGAGGA
CGAAACAGC 
MS2-B2ctrl MS2 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGTCCACCATCAGGGGACGGGACGGAGGA
CAAAACAGC 
MS2-B3 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTGGTCCACCATCAGGGGACTGGACTGAGGAC
GAAACAGC 
MS2-B4 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTCGTCCAGGATCACCGGACGGGACGGAGGA
CGAAACAGC 
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MS2-B5 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTCGTCCTAGGATCACCAGGACGGGACGGAG
GACGAAACAGC 
MS2-B6 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTCGTCCTAGGATCACCAGGAAGGGACGGAG
GACGAAACAGC 
MS2-B7 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTGTCCTAGGATCACCAGGAAGGGACGGAG
GACGAAACAGC 
MS2-B8 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTGCGTAGGATCACCACGTGGCGCGGAGGAC
GAAACAGC 
MS2-B9 MS2 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTGTAGGATCACCACACGGAGGACGAAACA
GC 
MS2-B10 MS2 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTGGTCCACCATCAGGGGACTGGACTGAGGAC
GAAACAGC 
MS2-B11 MS2 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGTCCTAGGATCACCAGGAAGGGACGGAG
GACGAAACAGC 
MS2-C1 MS2 GCTGTCACCGGATGTGCTGCAGGATCACCGCATTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGC 
MS2-C1ctrl MS2 GCTGTCACCGGATGTGCTGCAGGATCACCGCATTTCCGGTCTGATGAGTCCGTGAGGACAAAACAGC 
MS2-C2 MS2 GCTGTCACCGGATGTGGTTTCCGGTCTGATGAGTCCGACCATCAGGAGGACGAAACAGC 
MS2-C3 MS2 GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGACCATCAGGAGGACGAAACAGC 
MS2-C3ctrl MS2 GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGACCATCAGGAGGACAAAACAGC 
MS2-C4 MS2 GCTGTCACCGGATTCGGGATCCGGTCTGATGAGTCCGACCATCAGGAGGACGAAACAGC 
MS2-D1 MS2 
TGCTGTACGATCACGACAGCGGGCTAAAGCCCGC
TGTCACCGGATGTGCTTTCCGGTCTGATGAGTCC
GTGAGGACGAAACAGCGGGCC 
MS2-D2 MS2 
TGCTGCACGATCACGGCAGCGAGCTAAAGCTCGC
TGTCACCGGATGTGCTTTCCGGTCTGATGAGTCC
GTGAGGACGAAACAGCGGGCC 
MS2-D3 MS2 
TGCTGCAGGATCACCGCAGCGAGCTAAAGCTCGC
TGTCACCGGATGTGCTTTCCGGTCTGATGAGTCC
GTGAGGACGAAACAGCGAC 
MS2-D4 MS2 
TGCTTCATGATCACAGGAGCGGCACTAAAGTGCC
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTGAGGACGAAACAGCGGGCC 
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MS2-D5 MS2 
TAAAATAGTCATGATCACAGGCTGTCACCGGATG
TGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAA
CAGCCC 
MS2-D6 MS2 
TAAAATAGTTAGGATCACCGGCTGTCACCGGATG
TGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAA
CAGCCC 
PP7-1 PP7 coat protein 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGAGTTTATATGGAAACAGGACGAAACAGC 
PP7-2 PP7 GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGTGTTATATGGAACGGGACGAAACAGC 
PP7-3 PP7 GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGTTGGTATATGGACCGGGGACGAAACAGC 
Lambda-1 
Lambda N 
1-22 
peptide 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGTCCGAAGAGGACGGGACGGAGGACGAA
ACAGC 
Lambda-2 Lambda N 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGTCCTGAAGAAGGAAGGGACGGAGGACG
AAACAGC 
Lambda-3 Lambda N GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGTAGAGGACGAAACAGC 
Lambda-4 Lambda N GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCTGTAGAAGGACGAAACAGC 
p50-1 NF-κBp50 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTGGTATCCTGAAACTGTTATAAGGTTGGCC
GATGTTGGAGGACGAAACAGC 
p50-2 p50 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGGTATCCTGAAACTGTTATAAGGTTGGCC
GATGTTGGAGGACGAAACAGC 
p50-3 p50 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTGGGTATCCTGAAACTGTTATAAGGTTGGCC
GATGTTGGAGGACGAAACAGC 
p50-4 p50 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTGGGTATCCTGAAACTGTTATAAGGTTGGCC
GATGTTGGAGGACGAAACAGC 
p50-5 p50 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTGGTATCCTGAAACTGTTATAAGGTTGGCC
GATGTGTGGAGGACGAAACAGC 
p50-6 p50 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGGTATCCTGAAACTGTTATAAGGTTGGCC
GATGTGTGGAGGACGAAACAGC 
p50-7 p50 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTGTCCATCCTGAAACTGTTATAAGGTTGGC
CGATGGACGGATGGACGGAGGACGAAACAGC 
p50-8 p50 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGTCCATCCTGAAACTGTTATAAGGTTGGC
CGATGGACGGATGGACGGAGGACGAAACAGC 
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p50-9 p50 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTGTCCATCCTGAAACTGTTATAAGGTTGGC
CGATGGACAGATGGACGGAGGACGAAACAGC 
p50-10 p50 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTGTCCATCCTGAAACTGTTATAAGGTTGGC
CGATGGACAGATGGACGGAGGACGAAACAGC 
p50-11 p50 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTCATCCTGAAACTGTTATAAGGTTGGCCGAT
GGGGACGGAGGACGAAACAGC 
p50-12 p50 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTGTCCTTGAAACTGTAAGGTTGGCGGACGGG
ACGAGGACGAAACAGC 
p50-13 p50 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTCATCCTGAAACTGTTATAAGGTTGGCCGAT
GGGGACGAGGACGAAACAGC 
p65-1 NF-κBp65 
GCTGTCACCGGATGTGCTCGATGAGTCCGCGAGG
TGCCGAACCTCCATTGGGGTCGGTTTCCGGTCTG
ATGAGTCCGTGAGGACGAAACAGC 
p65-2 p65 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTTGATTCGATGAGTCCGCGAGGTGCCGAAC
CTCCATTGGGGTCGAGAGGACGAAACAGC 
p65-3 p65 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTTGATTCGATGAGTCCGCGAGGTGCCGAAC
CTCCATTGGGGTCGAGAGGACGAAACAGC 
p65-4 p65 
GCTGTCACCGGATGTGCTTTCCGGTCTGATGAGT
CCGTTTGATCGATGAGTCCGCGAGGTGCCGAACC
TCCATTGGGGTCGAGAGGACGAAACAGC 
p65-5 p65 
GCTGTCACCGGAATCAAGGTCCGGTCTGATGAGT
CCGTTTGATCGATGAGTCCGCGAGGTGCCGAACC
TCCATTGGGGTCGAGAGGACGAAACAGC 
Bcat-A1 β-catenin 
GACGTATGAGACTATGGACGCTATAGGCACACCG
GATACTTTAACGTCTCACTGATGAGGCCATGGCA
GGCCGAAACGTC 
Bcat-A2 β-catenin 
TACGTCTGAGCGTATGGACGCTATAGGCACACCG
GATACTTTAACCGCTCACTGAAGATGGCCCGGTA
GGGCCGAAACGTA 
Bcat-A3 β-catenin 
AAGAGGTCGGCACCTATGGACGCTATAGGCACA
CCGGATACTTTAACGGTGTCCTGATGAAGATCCA
TGACAGGATCGAAACCTCTT 
Bcat-A4 β-catenin 
CGCTGTCTGTACTTATGGACGCTATAGGCACACC
GGATACTTTAACAGTACACTGACGAGTCCCTAAA
GGACGAAACAGCG 
Bcat-B1 β-catenin 
GGCCGATCTATGGACGCTATAGGCACACCGGATA
CTTTAACGATTGGCTATAAAAGCTGTCACCGGAT
GTGCTTTCCGGTCTGATGAGTCCGTGAGGACGAA
ACAGCC 
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Bcat-B2 β-catenin 
GCCGATCTATGGACGCTATAGGCACACCGGATAC
TTTAACGATTGGCATAAAAGCTGTCACCGGATGT
GCTTTCCGGTCTGATGAGTCCGTGAGGACGAAAC
AGCC 
Bcat-B3 β-catenin 
TAGGCCGATCTATGGACGCTATAGGCACACCGGA
TACTTTAACGATTGGCTAAAAGCTGTCACCGGAT
GTGCTTTCCGGTCTGATGAGTCCGTGAGGACGAA
ACAGCC 
Bcat-B4 β-catenin 
TAAGCCGATCTATGGACGCTATAGGCACACCGGA
TACTTTAACGATTGGCAAAGCTGTCACCGGATGT
GCTTTCCGGTCTGATGAGTCCGTGAGGACGAAAC
AGCC 
Bcat-B5 β-catenin 
TAAAAACCAGCATCTATGGACGCTATAGGCACAC
CGGATACTTTAACGATGCTGTCACCGGATGTGCT
TTCCGGTCTGATGAGTCCGTGAGGACGAAACAGC
ATC 
Bcat-B6 β-catenin 
TAAAATCGCCGATCTATGGACGCTATAGGCACAC
CGGATACTTTAACGATTGGCTCACCGGATGTGCT
TTCCGGTCTGATGAGTCCGTGAGGACGAAAGCCA 
 
 
 
 
 
 
Supplementary Table 3.2.  Free energies (ΔG, kcal/mol) of individual conformations 
(ribozyme cleavage-active and -inactive) and the energy difference (ΔΔG, kcal/mol) 
predicted by RNAstructure 5.356. 
 aptamer unformed aptamer formed  
RNA device active inactive inactive active inactive - active 
sTRSV -19.3  N/A N/A 
sTRSVctrl  -19.3 N/A N/A 
MS2-A1 N/A  -23.2 N/A 
MS2-A2 N/A  -24.5 N/A 
MS2-A3 N/A  -31.1 N/A 
MS2-A4 N/A  -31.1 N/A 
MS2-A5 N/A  -30.2 N/A 
MS2-A6 N/A  -32.4 N/A 
MS2-A7 N/A  -27.1 N/A 
MS2-B1 -27.7  -26.9  0.8 
MS2-B2 -28.7  -27.3  1.4 
MS2-B2ctrl  -28.7 -27.3  N/A 
MS2-B3 -30.6  -29.1  1.5 
MS2-B4 -29.7  -28.5  1.2 
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MS2-B5 -30.4  -30.3  0.1 
MS2-B6 -30.4  -27.9  2.5 
MS2-B7 -28.5  -26.1  2.4 
MS2-B8 -27.4  -25.5  1.9 
MS2-B9 -22.7  -21.6  1.1 
MS2-B10 -29.7  -28.2  1.5 
MS2-B11 -27.5  -25.2  2.3 
MS2-C1  -24.6  -22.3 -2.3 
MS2-C1ctrl  -24.6 -22.3  N/A 
MS2-C2 -20.6  N/A N/A 
MS2-C3 -19.7  N/A N/A 
MS2-C3ctrl  -19.7 N/A N/A 
MS2-C4 -21.9  N/A N/A 
MS2-D1  -41.8  -40.7 -1.1 
MS2-D2  -39.1  -39.8 0.7 
MS2-D3  -36.2  -35.6 -0.6 
MS2-D4  -34.7  -34.3 -0.4 
MS2-D5 -23.6  -23.0  0.6 
MS2-D6 -23.8  -22.5  1.3 
PP7-1 -19.7  N/A N/A 
PP7-2 -19.6  N/A N/A 
PP7-3 -22.5  N/A N/A 
Lambda-1 -27.6  -25.2  2.4 
Lambda-2 -28.2  -23.9  4.3 
Lambda-3 -18.3  N/A N/A 
Lambda-4 -19.6  N/A N/A 
p50-1  -25.3  -24.8 -0.5 
p50-2  -24.4  -23.9 -0.5 
p50-3  -24.0  -23.7 -0.3 
p50-4  -23.7  -23.4 -0.3 
p50-5  -25.1  -23.0 -2.1 
p50-6  -24.8  -22.7 -2.1 
p50-7 -38.0  -36.3  1.7 
p50-8 -37.7  -36.0  1.7 
p50-9 -36.8  -36.2  0.6 
p50-10 -36.5  -35.9  0.6 
p50-11 -27.8  -26.1  1.7 
p50-12 -30.5  -28.3  2.2 
p50-13 -26.8  -26.1  0.7 
p65-1  -35.0  -34.4 -0.6 
p65-2 -36.0  -33.7  2.3 
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p65-3 -35.1  -32.8  2.3 
p65-4 -34.3  -34.1  0.2 
p65-5 -33.4  -33.2  0.2 
Bcat-A1 -21.0  N/A N/A 
Bcat-A2 -23.5  N/A N/A 
Bcat-A3 -23.8  N/A N/A 
Bcat-A4 -18.2  N/A N/A 
Bcat-B1  -31.3  -31.9 0.6 
Bcat-B2  -30.3  -31.3 1.0 
Bcat-B3  -33.1  -32.2 -0.9 
Bcat-B4  -30.9  -31.3 0.4 
Bcat-B5 -29.7  -28.8  0.9 
Bcat-B6 -27.2  -25.9  1.3 
 
 
 
 
 
 
Supplementary Table 3.3.  Primer and oligonucleotide sequences. 
Name DNA Sequence 
5’spacer AATAAATAAAA 
3’spacer CAAATAAACAAACACTC 
S 5’spacer AATAAA 
S 3’spacer AAATAAACAAACACTC 
lambda N 
TCGAGATGGACGCCCAGACCAGAAGGAGAGAGAGGAG
AGCCGAGAAGCAGGCCCAGTGGAAGGCCGCCAACTAG
CGGC 
insertNA CTGGCTAAAGGTGCGT 
No NLS A/X Fwd CAACTCGAGATGGTGGCTTCTAACTTTACTCAG 
DsRed A/X Rev CAAGGGCCCGCCGCTACTGGGAGC 
MS2 A/X Rev CAAGGGCCCGCCGCTAGTAGATGCCG 
EF1BFP Fwd CAAAGATCTGGATCTGCGATCGC 
EF1BFP Rev CAACCTAGGTCAATTAAGCTTGTGCCCCAG 
MS2 NotI F CAAGCGGCCGCTCGAGATGGCTTCTAACTTTACTCAGTTCGTTCTC 
MS2 ApaI R CAAGGGCCCGCCGCTAGTAGATGCCGGAGTTTGCT 
NLS MS2 F CAAGCGGCCGCTCGAGATGCCAAAGAAGAAGCGCAAAGTGGCTTCTAACTTTACTCAGTTCGTTCTC 
2MS2mut R AGCGGGTTTAAACGGGCCCGCCGCTA 
2MS2mut F GCAGATATCCAGCACAGTGGCGGCCGCTCGAGATG 
  
 III-74 
NES MS2 R CAAGGGCCCGCCGCTAGATGTCCAGTCCGGCCAGCTTCAGGGCCAGCTCGTTGTAGATGCCGGAGTTTGCT 
DsRed GF CCCGATTCCCTCGGCAATCGCAGCAAACTCCGGCATCTACG 
DsRed NES R 
AACTAGAAGGCACAGTCGAGGCTGATCAGCGGGTTTAA
ACGGGCCCGCCGCTAGATGTCCAGTCCGGCCAGCTTCA
GGGCCAGCTCGTTCTGGGAGCCGGAGTG 
DsRed GR AACTAGAAGGCACAGTCGAGG 
GF Clover CCTCGAGTATTCGCCACCATGGTGAGCAAGGGCG 
GR Clover GCGCGCCTTACCTAGGTTACTTGTACAGCTCGTCCATGC 
GF EF1 GCATGGACGAGCTGTACAAGTAACCTAGGTAAGGCGCGC 
GR EF1 CGCCCTTGCTCACCATGGTGGCGAATACTCGAGG 
PP7 NotI F CAAGCGGCCGCTCGAGATGGCCAAAACCATCGTTCT 
PP7 ApaI R CAAGGGCCCGCCGCTAGGAACGGCCCAGCG 
p50 NotI F CAAGCGGCCGCTCGAGATGGCAGAAGATGATCCATATTTGGGAAG 
p50 ApaI R CAAGGGCCCGCCGCTAGTCATCACTTTTGTCACAACCTTCA 
p65 NotI F CAAGCGGCCGCTCGAGATGGACGATCTGTTTCCCCT 
p65 ApaI R CAAGGGCCCGCCGCTAGGTCCTTTTCGCCTTCTCTTC 
b-cat NotI F CAAGCGGCCGCTCGAGATGCGTGCAATCCCTGAACTGA 
b-cat ApaI R CAAGGGCCCGCCGCTACTTGTCCTCAGACATTCGGAAC 
 
 
 
 
 
 
Supplementary Table 3.4.  Plasmid constructs. 
Plasmid Description 
pCS2304 pcDNA5/FRT with d2EGFP, bGHpA, and CMV-TetO2 inserted between AflII/KpnI 
pCS2359 pCS2304 with MS2-DsRedMonomer fusion protein inserted between XhoI/ApaI 
pCS2394 pCS2359 with sTRSV with spacers inserted between AvrII/AscI 
pCS2380 pCS2359 with MS2-A1 with spacers inserted between AvrII/AscI 
pCS2381 pCS2359 with MS2-A2 with spacers inserted between AvrII/AscI 
pCS2382 pCS2359 with MS2-A5 with spacers inserted between AvrII/AscI 
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pCS2383 pCS2359 with MS2-A6 with spacers inserted between AvrII/AscI 
pCS2406 pCS2359 with d2EGFP removed from NheI/AvrII 
pCS2409 pCS2406 with MS2 inserted between XhoI/ApaI 
pCS1 blank plasmid with no mammalian promoters (Maung Win) 
pCS339 pcDNA3.1(+) with chloramphenicol acetyltransferase (Chase Beisel) 
pCS1392 pcDNA5/FRT with FLAG-NLS-MS2-DsRedMonomer (Stephanie Culler) 
pCS2585 pcDNA5/FRT with EF1α-BFP-HSVTK (Melina Mathur) 
pCS2595 pCS2304 with EF1α-BFP inserted between BglII/AvrII and MS2 inserted between XhoI/ApaI 
pCS2602 pCS2595 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2601 pCS2595 with sTRSV with spacers inserted between AvrII/AscI 
pCS2615 pCS2595 with MS2-B1 with spacers inserted between AvrII/AscI 
pCS2616 pCS2595 with MS2-B2 with spacers inserted between AvrII/AscI 
pCS1697 pCS2595 with MS2-B2ctrl with spacers inserted between AvrII/AscI 
pCS2621 pCS2595 with MS2-B3 with spacers inserted between AvrII/AscI 
pCS2610 pCS2595 with MS2-B4 with spacers inserted between AvrII/AscI 
pCS2611 pCS2595 with MS2-B6 with spacers inserted between AvrII/AscI 
pCS2612 pCS2595 with MS2-B7 with spacers inserted between AvrII/AscI 
pCS2613 pCS2595 with MS2-B8 with spacers inserted between AvrII/AscI 
pCS2614 pCS2595 with MS2-B9 with spacers inserted between AvrII/AscI 
pCS2617 pCS2595 with MS2-C1 with spacers inserted between AvrII/AscI 
pCS1698 pCS2595 with MS2-C1ctrl with spacers inserted between AvrII/AscI 
pCS2618 pCS2595 with MS2-C2 with spacers inserted between AvrII/AscI 
pCS2619 pCS2595 with MS2-C3 with spacers inserted between AvrII/AscI 
pCS2385 pCS2595 with MS2-C3ctrl with spacers inserted between AvrII/AscI 
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pCS2620 pCS2595 with MS2-C4 with spacers inserted between AvrII/AscI 
pCS2595+MS2-D1 pCS2595 with MS2-D1 with S spacers inserted between AvrII/AscI 
pCS2595+MS2-D2 pCS2595 with MS2-D2 with S spacers inserted between AvrII/AscI 
pCS2606 pCS2595 with MS2-D3 with S spacers inserted between AvrII/AscI 
pCS2607 pCS2595 with MS2-D4 with S spacers inserted between AvrII/AscI 
pCS2608 pCS2595 with MS2-D5 with S spacers inserted between AvrII/AscI 
pCS2609 pCS2595 with MS2-D6 with S spacers inserted between AvrII/AscI 
pCS2631 pCS2595 with MS2mut inserted between NotI/ApaI 
pCS2632 pCS2631 with MS2-B1 with spacers inserted between AvrII/AscI 
pCS2633 pCS2631 with MS2-B2 with spacers inserted between AvrII/AscI 
pCS2650 pCS2631 with MS2-B3 with spacers inserted between AvrII/AscI 
pCS2651 pCS2631 with MS2-B7 with spacers inserted between AvrII/AscI 
pCS2634 pCS2631 with MS2-C1 with spacers inserted between AvrII/AscI 
pCS2635 pCS2631 with MS2-C3 with spacers inserted between AvrII/AscI 
pCS2653 pCS2631 with MS2-D5 with S spacers inserted between AvrII/AscI 
pCS2686 pCS2595 with 2MS2mut inserted between NotI/ApaI 
pCS2688 pCS2686 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2687 pCS2686 with sTRSV with spacers inserted between AvrII/AscI 
pCS2690 pCS2686 with MS2-B1 with spacers inserted between AvrII/AscI 
pCS2691 pCS2686 with MS2-B2 with spacers inserted between AvrII/AscI 
pCS2694 pCS2686 with MS2-B3 with spacers inserted between AvrII/AscI 
pCS2695 pCS2686 with MS2-B7 with spacers inserted between AvrII/AscI 
pCS2698 pCS2686 with MS2-B10 with spacers inserted between AvrII/AscI 
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pCS2699 pCS2686 with MS2-B11 with spacers inserted between AvrII/AscI 
pCS2692 pCS2686 with MS2-C1 with spacers inserted between AvrII/AscI 
pCS2693 pCS2686 with MS2-C3 with spacers inserted between AvrII/AscI 
pCS2697 pCS2686 with MS2-C4 with spacers inserted between AvrII/AscI 
pCS2696 pCS2686 with MS2-D5 with S spacers inserted between AvrII/AscI 
pCS2747 pCS2595 with NLS-2MS2mut inserted between NotI/ApaI 
pCS2749 pCS2747 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2748 pCS2747 with sTRSV with spacers inserted between AvrII/AscI 
pCS2750 pCS2747 with MS2-B1 with spacers inserted between AvrII/AscI 
pCS2751 pCS2747 with MS2-B2 with spacers inserted between AvrII/AscI 
pCS2758 pCS2747 with MS2-B11 with spacers inserted between AvrII/AscI 
pCS2752 pCS2747 with MS2-C1 with spacers inserted between AvrII/AscI 
pCS2753 pCS2747 with MS2-C3 with spacers inserted between AvrII/AscI 
pCS2759 pCS2747 with MS2-D5 with S spacers inserted between AvrII/AscI 
pCS2787 pCS2595 with 2MS2mut-NES inserted between NotI/ApaI 
pCS2789 pCS2787 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2788 pCS2787 with sTRSV with spacers inserted between AvrII/AscI 
pCS2790 pCS2787 with MS2-B1 with spacers inserted between AvrII/AscI 
pCS2791 pCS2787 with MS2-B2 with spacers inserted between AvrII/AscI 
pCS2798 pCS2787 with MS2-B11 with spacers inserted between AvrII/AscI 
pCS2792 pCS2787 with MS2-C1 with spacers inserted between AvrII/AscI 
pCS2793 pCS2787 with MS2-C3 with spacers inserted between AvrII/AscI 
pCS2799 pCS2787 with MS2-D5 with S spacers inserted between AvrII/AscI 
pCS2897 pCS2595 with 2MS2mut-DsRedMonomer 
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pCS2899 pCS2897 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2898 pCS2897 with sTRSV with spacers inserted between AvrII/AscI 
pCS2901 pCS2897 with MS2-B11 with spacers inserted between AvrII/AscI 
pCS2900 pCS2897 with MS2-C1 with spacers inserted between AvrII/AscI 
pCS2902 pCS2595 with NLS-2MS2mut-DsRedMonomer 
pCS2904 pCS2902 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2903 pCS2902 with sTRSV with spacers inserted between AvrII/AscI 
pCS2906 pCS2902 with MS2-B11 with spacers inserted between AvrII/AscI 
pCS2905 pCS2902 with MS2-C1 with spacers inserted between AvrII/AscI 
pCS2907 pCS2595 with 2MS2mut-DsRedMonomer-NES 
pCS2909 pCS2907 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2908 pCS2907 with sTRSV with spacers inserted between AvrII/AscI 
pCS2911 pCS2907 with MS2-B11 with spacers inserted between AvrII/AscI 
pCS2910 pCS2907 with MS2-C1 with spacers inserted between AvrII/AscI 
pCS1576 pcDNA3.1(+) with DsRed-Express 
pCS2391 pCS2595 with EF1α-Clover inserted between BglII/AvrII 
pCS2847 pCS2595 with PP7 inserted between NotI/ApaI 
pCS2847+sTRSVctrl pCS2847 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2847+sTRSV pCS2847 with sTRSV with spacers inserted between AvrII/AscI 
pCS2847+PP7-1 pCS2847 with PP7-1 with spacers inserted between AvrII/AscI 
pCS2847+PP7-2 pCS2847 with PP7-2 with spacers inserted between AvrII/AscI 
pCS2847+PP7-3 pCS2847 with PP7-3 with spacers inserted between AvrII/AscI 
pCS2816 pCS2595 with lambda N inserted between NotI/ApaI 
pCS2816+sTRSVctrl pCS2816 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2816+sTRSV pCS2816 with sTRSV with spacers inserted between AvrII/AscI 
pCS2816+Lambda-1 pCS2816 with Lambda-1 with spacers inserted between AvrII/AscI 
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pCS2816+Lambda-2 pCS2816 with Lambda-2 with spacers inserted between AvrII/AscI 
pCS2816+Lambda-3 pCS2816 with Lambda-3 with spacers inserted between AvrII/AscI 
pCS2816+Lambda-4 pCS2816 with Lambda-4 with spacers inserted between AvrII/AscI 
pCS2397 pCS2595 with insertNA inserted between NotI/ApaI 
pCS2666 pCS2397 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2665 pCS2397 with sTRSV with spacers inserted between AvrII/AscI 
pCS2672 pCS2397 with p50-1 with spacers inserted between AvrII/AscI 
pCS2673 pCS2397 with p50-2 with spacers inserted between AvrII/AscI 
pCS2674 pCS2397 with p50-3 with spacers inserted between AvrII/AscI 
pCS2675 pCS2397 with p50-4 with spacers inserted between AvrII/AscI 
pCS2676 pCS2397 with p50-5 with spacers inserted between AvrII/AscI 
pCS2677 pCS2397 with p50-6 with spacers inserted between AvrII/AscI 
pCS2668 pCS2397 with p50-7 with spacers inserted between AvrII/AscI 
pCS2669 pCS2397 with p50-8 with spacers inserted between AvrII/AscI 
pCS2670 pCS2397 with p50-9 with spacers inserted between AvrII/AscI 
pCS2671 pCS2397 with p50-10 with spacers inserted between AvrII/AscI 
pCS2683 pCS2397 with p50-11 with spacers inserted between AvrII/AscI 
pCS2684 pCS2397 with p50-12 with spacers inserted between AvrII/AscI 
pCS2685 pCS2397 with p50-13 with spacers inserted between AvrII/AscI 
pCS2682 pCS2397 with p65-1 with spacers inserted between AvrII/AscI 
pCS2678 pCS2397 with p65-2 with spacers inserted between AvrII/AscI 
pCS2679 pCS2397 with p65-3 with spacers inserted between AvrII/AscI 
pCS2680 pCS2397 with p65-4 with spacers inserted between AvrII/AscI 
pCS2681 pCS2397 with p65-5 with spacers inserted between AvrII/AscI 
pCS2604 pCS2391 with p50 inserted between NotI/ApaI 
pCS2605 pCS2391 with p65 inserted between NotI/ApaI 
pCS2766 pCS2397 with Bcat-A1 with spacers inserted between AvrII/AscI 
pCS2767 pCS2397 with Bcat-A2 with spacers inserted between AvrII/AscI 
pCS2768 pCS2397 with Bcat-A3 with spacers inserted between AvrII/AscI 
pCS2769 pCS2397 with Bcat-A4 with spacers inserted between AvrII/AscI 
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pCS2397+Bcat-B1 pCS2397 with Bcat-B1 with S spacers inserted between AvrII/AscI 
pCS2397+Bcat-B2 pCS2397 with Bcat-B2 with S spacers inserted between AvrII/AscI 
pCS2397+Bcat-B3 pCS2397 with Bcat-B3 with S spacers inserted between AvrII/AscI 
pCS2397+Bcat-B4 pCS2397 with Bcat-B4 with S spacers inserted between AvrII/AscI 
pCS2397+Bcat-B5 pCS2397 with Bcat-B5 with S spacers inserted between AvrII/AscI 
pCS2397+Bcat-B6 pCS2397 with Bcat-B6 with S spacers inserted between AvrII/AscI 
pCS2824 pCS2595 with β-catenin Arm 1-12 inserted between NotI/ApaI 
pCS2850 pCS2824 with sTRSVctrl with spacers inserted between AvrII/AscI 
pCS2849 pCS2824 with sTRSV with spacers inserted between AvrII/AscI 
pCS2824+Bcat-A1 pCS2824 with Bcat-A1 with spacers inserted between AvrII/AscI 
pCS2824+Bcat-A2 pCS2824 with Bcat-A2 with spacers inserted between AvrII/AscI 
pCS2824+Bcat-A3 pCS2824 with Bcat-A3 with spacers inserted between AvrII/AscI 
pCS2848 pCS2824 with Bcat-A4 with spacers inserted between AvrII/AscI 
pCS2824+Bcat-B1 pCS2824 with Bcat-B1 with S spacers inserted between AvrII/AscI 
pCS2824+Bcat-B2 pCS2824 with Bcat-B2 with S spacers inserted between AvrII/AscI 
pCS2824+Bcat-B3 pCS2824 with Bcat-B3 with S spacers inserted between AvrII/AscI 
pCS2824+Bcat-B4 pCS2824 with Bcat-B4 with S spacers inserted between AvrII/AscI 
pCS2824+Bcat-B5 pCS2824 with Bcat-B5 with S spacers inserted between AvrII/AscI 
pCS2824+Bcat-B6 pCS2824 with Bcat-B6 with S spacers inserted between AvrII/AscI 
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Supplementary Table 3.5.  Human cell lines with stably integrated constructs. 
Parental line Integrated plasmid construct 
Flp-In T-REx HEK293 pCS2359 
Flp-In T-REx HEK293 pCS2380 
Flp-In T-REx HEK293 pCS2381 
Flp-In T-REx HEK293 pCS2382 
Flp-In T-REx HEK293 pCS2383 
Flp-In T-REx HEK293 EF1α-GFP (Ryan Bloom) 
Flp-In HEK293 pCS2585 (Melina Mathur) 
Flp-In T-REx HEK293 pCS2595 
Flp-In T-REx HEK293 pCS2686 
Flp-In T-REx HEK293 pCS2688 
Flp-In T-REx HEK293 pCS2699 
Flp-In T-REx HEK293 pCS2692 
Flp-In T-REx HEK293 pCS2693 
Flp-In T-REx HEK293 pCS2696 
Flp-In T-REx HEK293 pCS2747 
Flp-In T-REx HEK293 pCS2749 
Flp-In T-REx HEK293 pCS2758 
Flp-In T-REx HEK293 pCS2752 
Flp-In T-REx HEK293 pCS2753 
Flp-In T-REx HEK293 pCS2759 
Flp-In T-REx HEK293 pCS2787 
Flp-In T-REx HEK293 pCS2789 
Flp-In T-REx HEK293 pCS2798 
Flp-In T-REx HEK293 pCS2792 
Flp-In T-REx HEK293 pCS2793 
Flp-In T-REx HEK293 pCS2799 
Flp-In T-REx HEK293 pCS2899 
Flp-In T-REx HEK293 pCS2898 
Flp-In T-REx HEK293 pCS2901 
Flp-In T-REx HEK293 pCS2900 
Flp-In T-REx HEK293 pCS2904 
Flp-In T-REx HEK293 pCS2903 
Flp-In T-REx HEK293 pCS2906 
Flp-In T-REx HEK293 pCS2905 
Flp-In T-REx HEK293 pCS2909 
Flp-In T-REx HEK293 pCS2908 
Flp-In T-REx HEK293 pCS2911 
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Flp-In T-REx HEK293 pCS2910 
Flp-In T-REx HEK293 pCS2824 
Flp-In T-REx HEK293 pCS2850 
Flp-In T-REx HEK293 pCS2849 
Flp-In T-REx HEK293 pCS2848 
 
 
 
 
 
 
Supplementary Table 3.6.  Alternate names of RNA devices. 
RNA device Name in notebooks  RNA device Name in notebooks 
MS2-A1 LI AU  PP7-3 PP7-3 
MS2-A2 LI CU  Lambda-1 L2b8-a1-lambda 
MS2-A3 LII UG  Lambda-2 L85-a1-lambda 
MS2-A4 LII UG CtoG  Lambda-3 lambda-4 
MS2-A5 LII UG a1  Lambda-4 lambda-5 
MS2-A6 LII UG a14  p50-1 p50-OFF1 
MS2-A7 LII GA  p50-2 p50-OFF1-a1 
MS2-B1 D1  p50-3 p50-OFF2 
MS2-B2 D2  p50-4 p50-OFF2-a1 
MS2-B2ctrl D2ctrl  p50-5 p50-OFF3 
MS2-B3 D7  p50-6 p50-OFF3-a1 
MS2-B4 L81  p50-7 p50-ON1 
MS2-B5 L83  p50-8 p50-ON1-a1 
MS2-B6 L84  p50-9 p50-ON2 
MS2-B7 L85  p50-10 p50-ON2-a1 
MS2-B8 L61  p50-11 U12N11 
MS2-B9 L41  p50-12 U1N1 
MS2-B10 D7-a1  p50-13 U11N11 
MS2-B11 L85-a1  p65-1 p65-OFF1 
MS2-C1 D3  p65-2 p65-ON1 
MS2-C1ctrl D3ctrl  p65-3 p65-ON1-a1 
MS2-C2 D4  p65-4 p65-ON2 
MS2-C3 D5  p65-5 p65-ON2-a1 
MS2-C3ctrl D5ctrl  Bcat-A1 Bcat-sLTSV- 
MS2-C4 D6  Bcat-A2 Bcat-sLTSV+ 
MS2-D1 J1  Bcat-A3 Bcat-CChMVd- 
MS2-D2 J2  Bcat-A4 Bcat-SCMoV+ 
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MS2-D3 J3  Bcat-B1 Bcat-OFF3 
MS2-D4 J4   Bcat-B2 Bcat-OFF4 
MS2-D5 J5  Bcat-B3 Bcat-OFF5 
MS2-D6 J6  Bcat-B4 Bcat-OFF6 
PP7-1 D5-PP7  Bcat-B5 Bcat-ON3 
PP7-2 PP7-2  Bcat-B6 Bcat-ON4 
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Chapter 4 
 
 
 
Conclusions  
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The emerging field of synthetic biology has produced a vast array of engineered 
molecular devices, enabling investigation of cellular function and programmed control of 
new phenotypic behaviors in biological systems1–4.  These devices are generally 
composed of protein or RNA, two biological macromolecules whose sequence 
determines their three-dimensional shape, dictating their ability to bind to other 
molecules and catalyze chemical reactions.  RNA and protein engineering have greatly 
expanded the capabilities of these macromolecules, enabling functions not found in 
natural biological systems3,5–8. 
Synthetic molecular devices have been used to regulate gene expression in a wide 
variety of organisms, from prokaryotes to microbial eukaryotes to humans9–11.  Some of 
these genetic control platforms are able to process molecular input into increases or 
decreases in gene expression output by combining a sensor component with an actuator 
component1,12.  Such platforms exhibit the greatest utility when the components are easy 
to design and optimize, and when different components can be integrated together in 
predictable ways without disrupting their individual functions. 
RNA is particularly well suited as a substrate for the implementation of molecular 
gene-regulatory devices.  RNA molecules can hybridize with RNA and DNA through 
base-pairing interactions, and bind to small molecules and proteins by adopting specific 
conformations13,14.  They are also able to catalyze various chemical reactions, including 
the lysis of phosphodiester bonds15,16.  The binding and catalytic functions of RNA 
strands are largely dictated by their secondary structure, which can be predicted by 
computational models of RNA folding17–19.  In contrast, protein function largely depends 
on complex tertiary interactions, which are currently far more challenging to predict from 
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the primary sequence alone.  Furthermore, the ability of RNA to be replicated by reverse 
transcription and PCR enables the facile in vitro selection of RNA molecules with novel 
functions from large libraries of different sequences20,21. 
The ability of RNA enzymes to cleave phosphodiester bonds is exploited in the 
engineering of the ribozyme switch platform, in which cleavage of an mRNA strand by a 
hammerhead ribozyme causes silencing of the encoded gene in response to ligand 
binding to an aptamer12.  With the aid of structure prediction software, ribozyme switches 
were designed to adopt distinct cleavage-active and cleavage-inactive conformations, 
with ligand binding stabilizing the conformation in which the aptamer sensor component 
is properly formed12.  Both ON and OFF switches were demonstrated to regulate gene 
expression in yeast and mammalian cells and, importantly, replacement of the aptamer 
component to sense an alternate ligand did not require extensive redesign of the 
device12,22,23.  However, the platform was limited to the regulation of transgenes in 
response to small molecule inputs. 
We attempted to extend the capabilities of the ribozyme switch platform to two 
new functions: the regulation of endogenous genes and the sensing of protein inputs.  We 
were unable to demonstrate ribozyme activity in trans, and the limitations we discovered 
suggest that this platform is not as promising as other trans-acting platforms such as those 
based on RNAi24–26 and CRISPRi27.  We were successful, however, in developing novel 
protein-responsive ribozyme switches for regulating genes in cis in human cells.  We 
demonstrated a higher level of ligand-responsiveness than previously described small-
molecule-responsive ribozyme switches in mammalian systems, and we showed that 
cytoplasmic and nuclear localization of ligand were each sufficient to elicit switching 
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activity.  We also demonstrated the versatility of our switch platform with a ribozyme 
switch responsive to an alternative protein ligand. 
In our attempts to develop new devices responsive to various protein ligands, we 
found that integration of aptamers into the platform is a challenging process.  Further 
study is needed in order to extend our platform to diverse ligands, making the process of 
generating new devices more reliable and straightforward.  We rationally designed each 
device presented here, but in the future a wider sequence space could be explored using 
high-throughput in vivo screening methods20,28,29 to assay large libraries of randomized 
devices.  As new sensor components are generated by in vitro selection, we hope that 
improved screening strategies will enable them to be integrated into our switch platform. 
Our ribozyme switch is able to respond to proteins in either the nucleus or the 
cytoplasm, while previously described mammalian gene-regulatory devices have required 
specific localization of ligand in order to produce a switching response.  Our platform is 
therefore unable to detect changes in protein distribution across subcellular 
compartments, but it is more versatile than previous platforms in that ligand input choice 
is not restricted to proteins localized to just one compartment. 
We developed a device responsive to β-catenin, a signaling protein with an 
important role in cancer30.  This device and other ribozyme switches that respond to 
disease markers could be used to noninvasively detect diseased cellular states.  
Furthermore, such switches could be used to control cell fate by, for example, regulating 
the expression of a proapoptotic transgene.  In this way a genetically encoded therapeutic 
effect could be targeted to diseased cells while leaving healthy cells unaffected.  
Coupling our device with other synthetic biology components such as positive feedback 
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or amplifier systems could expand the dynamic range of switch response and enable 
tuning of activity to match application-specific phenotypic thresholds.  As the field of 
synthetic biology continues to advance, we hope the molecular device platform we have 
developed will be a useful tool for protein-responsive gene regulation.  
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